Quantitative Analysis of Influenza Virus-Specific B Cell Responses Generated by Infection and Vaccination by Joo, Hye Mee
University of Tennessee, Knoxville
Trace: Tennessee Research and Creative
Exchange
Doctoral Dissertations Graduate School
8-2009
Quantitative Analysis of Influenza Virus-Specific B
Cell Responses Generated by Infection and
Vaccination
Hye Mee Joo
University of Tennessee - Chattanooga
This Dissertation is brought to you for free and open access by the Graduate School at Trace: Tennessee Research and Creative Exchange. It has been
accepted for inclusion in Doctoral Dissertations by an authorized administrator of Trace: Tennessee Research and Creative Exchange. For more
information, please contact trace@utk.edu.
Recommended Citation
Joo, Hye Mee, "Quantitative Analysis of Influenza Virus-Specific B Cell Responses Generated by Infection and Vaccination. " PhD
diss., University of Tennessee, 2009.
https://trace.tennessee.edu/utk_graddiss/52
To the Graduate Council:
I am submitting herewith a dissertation written by Hye Mee Joo entitled "Quantitative Analysis of
Influenza Virus-Specific B Cell Responses Generated by Infection and Vaccination." I have examined the
final electronic copy of this dissertation for form and content and recommend that it be accepted in
partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in
Comparative and Experimental Medicine.
Mark Y. Sangster, Major Professor
We have read this dissertation and recommend its acceptance:
Barry T. Rouse, Tim Sparer, Stephen J. Kennel
Accepted for the Council:
Dixie L. Thompson
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)
To the Graduate Council:  
I am submitting herewith a dissertation written by Hye Mee Joo entitled “Quantitative analysis of 
influenza virus-specific B cell responses generated by infection and vaccination.” I have 
examined the final electronic copy of this dissertation for form and content and recommend that 
it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, 
with a major in Comparative and Experimental Medicine.  
                                         
 
                                                                                                                      Mark Y. Sangster  
                                                                                                                      Major Professor  
We have read this dissertation  
and recommend its acceptance:  
 
Barry T. Rouse 
Tim Sparer 
Stephen J. Kennel  
                                                                                                             
                                                                                                      Accepted for the Council:  
 
Carolyn R. Hodges 
                                                                                              Vice Chancellor and  
                                                                                                        Dean of Graduate Studies  
 
 
(Original signatures are on file with official student records)
Quantitative analysis of influenza virus-specific B cell 
responses generated by infection and vaccination 
 
 
 
 
A Dissertation Presented for the 
Doctor of Philosophy Degree 
The University of Tennessee, Knoxville 
 
 
 
Hye Mee Joo 
August 2009 
ii 
 
DEDICATION 
 
This dissertation is simply impossible without my parents, Dong-Choon Joo and Soon-
Seok Hong. They bore me, raised me, loved me, and supported me spiritually throughout my life. 
To them I dedicate this thesis. 
 
 
 
 
 
 
 
 
iii 
 
ACKNOLWLEDGEMENTS 
It is a pleasure to thank the many people who made this thesis possible. Foremost, I 
would like to express my sincere gratitude to my advisor Dr. Mark Sangster for the continuous 
support of my Ph. D study and research, for his patience, motivation, enthusiasm and immense 
knowledge. His guidance helped me in all the time of research and writing of this thesis. In 
addition, he was always accessible and willing to help his students. As a result, research life 
became smooth and rewarding for me. I could not have imagined having a better advisor and 
mentor for my Ph. D study.  
I gratefully acknowledge the members of my committee, Dr. Barry T. Rouse, Dr. Tim 
Sparer and Dr. Stephen J. Kennel, as well as Dr. Thandy Onami for all their time and helpful 
guidance.  
My special thanks go in particular to Linda Sangster who has served as a mother figure to 
me over the last five years. I greatly appreciate her help in keeping the lab running smoothly. 
I would also like to thank my lab buddies : Arthie Sundararajan and Lifang Huan for their 
friendship and help in the past three years. All other folks, including Junwei Jiang and  John 
Harp had inspired me in research and life through our interactions during the long hours in the 
lab. Thanks.  
My deepest gratitude goes to my parents who always besides me and encouraged me to 
come this far. I am eternally grateful for their inseparable support and prayers.  My brother, 
Sehwan Joo, thanks for being supportive and caring siblings. 
iv 
 
Last but not the least, I greatly express my appreciation to my husband Jae Hoon Bahn 
for his dedication, love and persistent confidence in me. Thanks for putting up with me through 
this process. I could not have done this without you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ABSTRACT 
The two cellular components of B cell memory are antibody (Ab)-secreting cells (ASCs) and 
memory B cells (BMem). BMem are quiescent cells that respond to “recall” antigen and contribute 
substantially to vaccine effectiveness. The rational evaluation of vaccination strategies is 
dependent on quantitative information on the state of B cell memory. Despite the importance of 
BMem in resistance to infection, there is little information on the nature of BMem populations 
generated by influenza infection or vaccination. The major goal of this dissertation was a 
comprehensive quantitative analysis of the frequency and distribution of influenza-specific BMem 
generated by influenza infection of the respiratory tract, or by vaccination with inactivated virus.  
To achieve this, a prerequisite was the development of a sensitive and reproducible 
limiting dilution assay (LDA) for determining influenza-specific BMem frequencies. The results in 
Chapter 2 demonstrated that a strategy utilizing BPL-inactivated virus particles was effective  for 
the in vitro activation of virus-specific BMem. This strategy selectively activates virus-specific 
BMem and, importantly, achieves this without a requirement for CD4+ T cell associated factors. 
Using this strategy, the frequency of Influenza specific BMem in different anatomical sites 
was measured and we also tested three different forms of influenza virus immunization strategy; 
(i) intranasal (i.n.) infection, (ii) i.n. vaccination, (iii) intramuscular (i.m.) vaccination. The 
results in Chapter III, IV showed that following different forms of immunization, BMem dispersed 
broadly to organized lymphoid tissues throughout the body, and a population of ASCs was 
established in the bone marrow. ASC and BMem frequencies in these locations reflected the 
magnitude of the primary B cell response to the form of immunization. Thus, the frequencies 
were higher following i.n. infection. Interestingly, the state of B cell memory in the lung was 
vi 
 
profoundly influenced by the form of immunization. The lung was a preferential site of BMem 
localization after i.n. infection. However, this was not the case after i.m. immunization when 
BMem frequencies in the lung were considerably lower than in other sites. Our findings point to an 
effect of influenza infection on the lung environment that profoundly influences ASC and BMem 
trafficking to this site.  
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Introduction 
Influenza is a contagious respiratory viral illness of global importance and is a significant cause 
of morbidity and mortality annually. Four or five pandemics of influenza occurred during 
the last century with intervals of 9-39 years. By far the worst was the pandemic of 1918 – 1920. 
Over a 10-month period, this "Spanish flu" killed an estimated 40-50 million people worldwide 
with many of the deaths occurring in young, previously healthy adults.  
When symptomatic, influenza typically produces an acute febrile illness characterized by 
cough, headache and myalgia. The majority of morbidity and mortality occurs in the elderly with 
underlying chronic cardiorespiratory disease or diabetes mellitus, particularly those in residential 
care. Complications of acute influenza include viral and secondary bacterial pneumonias, 
exacerbations of pre-existing cardiopulmonary disease and, in children and infants, croup, otitis 
media, bronchiolitis and febrile convulsions (Glezen 1982; Nicholson 1992). 
Each year, circulating influenza viruses are responsible for approximately 40,000 deaths 
and up to 150,000 hospitalizations in the United States (Thompson, Shay et al. 2003; Harper, 
Fukuda et al. 2005).  On top of this are growing concerns of a developing influenza pandemic. 
Avian influenza viruses of the H5N1 subtype with potential for high virulence in humans 
continue to expand their distribution from initial sites of emergence in Southeast Asia. Mutations 
that enable efficient spread of H5N1 viruses within an immunologically naïve human population 
may occur and serve as a pandemic trigger. Clearly, there is a strong need to continue to develop 
and improve strategies to combat influenza. 
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The challenge of antigenic change in influenza viruses 
Influenza viruses have segmented genomes and show great antigenic diversity. Of the 
three types of influenza viruses-A, B, and C-only types A and B cause widespread outbreaks. 
Influenza A viruses are classified into subtypes based on antigenic differences between their two 
surface glycoproteins, haemagglutinin and neuraminidase. 15 haemagglutinin subtypes (H1–H15) 
and nine neuraminidase subtypes (N1–N9) have been identified for influenza A viruses. 
Viruses of all haemagglutinin and neuraminidase subtypes have been recovered from aquatic 
birds, but only three haemagglutinin subtypes (H1, H2, and H3) and two neuraminidase subtypes 
(N1 and N2) have established stable lineages in the human population since 1918. Only one 
subtype of haemagglutinin and one of neuraminidase are recognised for influenza B viruses.  
Haemagglutinin facilitates entry of the virus into host cells through its attachment to sialic-acid 
receptors. It is the major antigenic determinant of type A and B viruses to which neutralizing 
antibodies (Abs) are directed and the crucial component of current influenza vaccines. Five Ab-
combining sites have been mapped on the HA of H3 subtype human influenza A viruses (Wilson 
and Cox 1990); however, less is known about HAs of avian influenza A subtypes. 
An important function of neuraminidase, the second major antigenic determinant, is to 
catalyze the cleavage of glycosidic linkages to sialic acid, thereby assisting in the release of 
progeny virions from infected cells. Accordingly, neuraminidase has become an important target 
for antiviral activity. The M2 ion channel of influenza A, which is blocked by the antiviral drug 
amantadine, regulates the internal pH of the virus, which is crucial during early viral replication. 
Influenza vaccination is the primary method for preventing influenza and its severe 
complications. However, the biology of influenza virus presents a major challenge to effective 
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vaccination. Influenza viruses utilize two mechanisms, referred to as antigenic drift and antigenic 
shift, to evade the human immune response. Point mutations that occur during viral replications 
continuously generate antigenic change (antigenic drift), especially in the surface hemagglutinin 
(HA) and neuraminidase (NA) glycoproteins of influenza A viruses. These surface molecules are 
the basis for categorizing influenza A viruses into subtypes (e.g. H3N2, H1N1). Abs induced by 
vaccination with one antigenic form may confer profound protection against infection with the 
homologous virus. However, the protection may be substantially less against a “drifted” variant, 
even though the viral subtype remains the same. As a general rule, Abs raised against one 
subtype provide little, if any, protection against a completely novel subtype. This feature enables 
the virus to evade immune recognition, leading to repeated outbreaks during interpandemic years.  
Antigenic shift is a rare but occurs with the emergence of a “new”, potentially pandemic, 
influenza A virus that possesses a novel HA alone or with a novel NA. The novel HA and NA 
genes in pandemic influenza viruses are derived from the reservoir of avian influenza viruses in 
nature (Reid, Fanning et al. 2004; Reid, Taubenberger et al. 2004). The new virus is antigenically 
distinct from circulating human influenza viruses and Abs towards the previously circulation 
subtype do not cross-react with the new subtype. 
A major goal of influenza vaccination is to generate broad protection against variants 
within a subtype (heterovariant protection) and, optimally, against a range of different subtypes 
(heterosubtypic protection).  
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Human influenza vaccines 
Since the 1940s, inactivated influenza vaccines have been developed for the control of 
annual influenza epidemics (Hilleman 2000). Two forms of influenza vaccine are currently 
licensed for use in humans in the United States: (i) an inactivated vaccine administered 
intramuscularly (i.m.), and (ii) a live attenuated intranasal (i.n.) vaccine. Both vaccine forms are 
prepared from the same set of three viruses, two influenza A viruses and an influenza B virus, 
that are predicted to match the predominant circulating viruses in the next flu season.  
Three types of inactivated influenza vaccine are currently recommended by WHO; whole 
virus, detergent-treated split product and purified surface antigen. All commercially produced 
influenza vaccines are grown in eggs and inactivated by either formaldehyde or β-propiolactone 
(Davenport, Hennessy et al. 1964; Bachmayer 1975; Brady and Furminger 1976; Brady and 
Furminger 1976). Early whole virion inactivated vaccines were associated with frequent local 
and systemic adverse effects in young children(Davenport, Hennessy et al. 1964). Accordingly, 
whole virion influenza vaccines are little used and are unlicensed in many countries.  At the 
present time, inactivated split-virus and subunit influenza vaccines receive more widespread use, 
and it is the only vaccine form approved for administration to children aged <5 years and adults 
aged ≥50 years. 
Intranasal delivery of live influenza vaccines offers the advantage of mimicking natural 
infection, thereby providing a broader immunological response and more durable protection than 
with inactivated vaccines (Murphy and Clements 1989; Murphy and Coelingh 2002). However, 
in the United States, live attenuated virus vaccine is only approved for the age group of 5-49, 
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thus excluding two major high-risk groups, infants and the elderly, in addition to 
immunocompromised patients and pregnant woman. 
.  A key determinant of the efficacy of both vaccine forms is the ability to induce strong B 
cell responses against the component viruses. The inactivated vaccine is essentially a “B cell 
vaccine”. Protective efficacy of the live vaccine is also ascribed primarily to the induction of 
virus-specific Abs (Murphy and Coelingh 2002), although replicating virus also facilitates 
priming of virus-specific cytotoxic T cells (Gorse, Campbell et al. 1995). The key point is that B 
cell responses are of central importance in vaccine-induced protection against influenza. More 
precisely, it is the vaccine-induced state of B cell memory that is all important. 
 
Immune responses and memory in a mouse model of influenza infection   
Influenza virus infection of the respiratory tract in mice is a well-characterized model that 
has many features in common with human influenza infection. This model has been used 
extensively to study the immune response to infection and vaccination, and to identify the 
components of the adaptive immune response that are most effective in mediating virus 
clearance and providing protection against re-infection (Doherty, Topham et al. 1997; Gerhard, 
Mozdzanowska et al. 1997). 
Influenza viruses infect epithelial cells of the upper respiratory tract and bronchi, as well 
as mononuclear cells (Ronni, Sareneva et al. 1995). Intranasal administration of the A/HKx31 
(H3N2) influenza A virus to C57BI/6J (B6) mice leads to the development of primary viral 
pneumonia. In the B6 model, virus is cleared 10 days after infection, with no indication of 
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persistent antigen or viral RNA (Allan, Tabi et al. 1990). Recovery or prevention of influenza 
relies on both innate and adaptive response in the immunologically intact mouse. This has been 
evidenced by increased mortality or delayed recovery of mice that have a defective type I 
interferon response system (Lindenmann, Lane et al. 1963; Haller, Arnheiter et al. 1979; Garcia-
Sastre, Durbin et al. 1998) or complement system (Hicks, Ennis et al. 1978; Kopf, Abel et al. 
2002) or are deficient in major histocompatibility complex class I (MHC-I)-restricted CD8+ T 
(Bender, Croghan et al. 1992) or B cells (Gerhard, Mozdzanowska et al. 1997; Graham and 
Braciale 1997; Topham and Doherty 1998; Baumgarth, Herman et al. 2000; Kopf, Brombacher 
et al. 2002; Webby, Andreansky et al. 2003). 
 
Innate response to influenza virus infection 
Respiratory epithelial cells are the primary targets for influenza A virus infection. This 
localized pathology reflects that the production of new virus requires cleavage of the surface HA 
molecule by an enzyme restricted in distribution to the superficial epithelial layer of the 
respiratory tract (Walker, Sakaguchi et al. 1992; Rott, Klenk et al. 1995). Following influenza 
infection, respiratory epithelial cells produce large amounts of virus which can then infect 
alveolar macrophages and immature respiratory dentritic cells (RDC). In addition, cell 
necrosis/apoptosis triggers innate immune responses and local production of cytokines such as 
type I interferon, TNF-α, IL-12,  IL-1 and chemokines such as monocyte chemoattractant 
protein-1 (MCP-1), regulated on activation, normal T-cell expressed and secreted (RANTES), 
MIP-1α/β, interferon induced protein (IP-10) (Matsukura, Kokubu et al. 1996; Sprenger, Meyer 
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et al. 1996; Adachi, Matsukura et al. 1997; Bussfeld, Kaufmann et al. 1998; Dawson, Beck et al. 
2000). These proinflammatory cytokines and chemokines produced by infected cells cause the 
extravasation of small numbers of blood-derived neutrophils initially, followed by larger 
numbers of blood monocytes/macrophages from the peripheral blood across the endo-epithelial 
barrier into infected lung tissue within the first 3 days after influenza A virus infection (Table 1.) 
(Ada and Jones 1986; La Gruta, Kedzierska et al. 2007). During this period, viral replication 
continues in the epithelial cells and infection spreads to the recruited macrophages (Fujisawa, 
Tsuru et al. 1987; Hofmann, Sprenger et al. 1997). These processes alone are not able to clear the 
virus from the lung. By day 7, CD8+ cytotoxic T cells (CTLs) from mediastinal lymph nodes 
begin to accumulate in the infected lung and the efficient process of T cell mediated viral 
clearance begins (Bender and Small 1992; Shaw, Arden et al. 1992). 
 
Adaptive response to influenza virus infection 
The adaptive response to influenza virus is mediated by neutralizing antibody producing 
B cells, and CD4+ helper T cells, and CD8+ cytotoxic T lymphocytes (CTL) that kill infected 
cells (Doherty, Topham et al. 1997; Gerhard, Mozdzanowska et al. 1997; Topham, Tripp et al. 
1997; Doherty and Christensen 2000; Wong and Pamer 2003; Brown, Roman et al. 2004). To 
initiate anti-influenza adaptive immune  response, Antigen presenting cells (macrophages and 
DCs) are essential. Influenza infection via TLR3, TLR7/8 results in DC activation, maturation 
and migration of the DC from the respiratory tract through the afferent lymphatics to draining 
lymph nodes (Figure 1). DC then present viral antigen to virus-specific naïve T cells which 
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triggers T cell activation/differentiation. influenza-specific naïve T cells can differentiate into 
Th1 and Th2. Th1 cells secrete IFN-γ, IL-2 and help IgG2a/c Ab production, while Th2 cell 
secrete IL-4 and IL-5 and help IgA, IgG1 Ab production (Ada and Jones 1986) in the germinal 
center of the lymph node.  Each antibody isotype produced during the immune response is 
known to have  specific functions (Table 2.). Typically, influenza infection leads to a strong Th1 
type of response followed by dominating IgG2a/c production (Sangster, Riberdy et al. 2003).  
Th1 cells are  also essential in the generation and maintenance of CD8+ T cell memory by 
secreting IL-2, though in the primary response, CD4+ T cells are not required for expansion or 
development of functional CD8+ CTL (Riberdy, Christensen et al. 2000; Thomas, Keating et al. 
2006). 
The consequences of the immune response in the lymph node, production of influenza-
specific Abs contributing to viral neutralization due to binding with viral antigen. In addition, 
differentiated effector T cells can leave the draining lymph nodes through the efferent lymphatics 
and circulatory system and then localize to infected lung (Legge and Braciale 2003; Langlois and 
Legge 2007).  
 
Characteristics of B cell memory 
Studies of the mouse model have established that influenza infection elicits a vigorous 
primary B cell response and extensive anti-viral Ab production that contributes substantially to 
virus clearance and recovery (Gerhard, Mozdzanowska et al. 1997). A consequence of this B cell 
response is a state of B cell memory that provides profound long-term protection against re-
infection with the same virus or an antigenically related virus. Two components of B cell 
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memory can be identified: (i) plasma cells, and (ii) BMem. Long-lived plasma cells (Slifka, Antia 
et al. 1998) secreting high affinity anti-viral Abs are found predominantly in the bone marrow 
(Hyland, Sangster et al. 1994; Sangster, Hyland et al. 1995; Slifka, Matloubian et al. 1995) and at 
mucosal surfaces (Liang, Hyland et al. 2001). IgA Abs produced by sub-mucosal plasma cells, 
and serum IgG derived from the bone marrow plasma cell population, provide anti-viral activity 
in the upper and lower respiratory tract, respectively. BMem are also long-lived (Schittek and 
Rajewsky 1990) but, unlike plasma cells, they are quiescent, non-Ab-secreting cells that 
distribute to lymphoid tissues throughout the body (Bachmann, Kundig et al. 1994; Slifka and 
Ahmed 1996). If a previously encountered virus manages to escape the barrier of pre-existing 
Abs and re-establishes an infection, BMem are stimulated to produce a secondary anti-viral Ab 
response that is even more rapid and effective than the primary response (Sangster, Smith et al. 
1995). Thus, a BMem response functions to greatly curtail the duration and severity of infection. 
 
Characteristics of memory B cells 
The BMem generated in germinal centers as part of T cell-dependent B cell responses 
(McHeyzer-Williams, Driver et al. 2001) typically express an isotype-switched surface Ig 
receptor (IgG, IgA, or IgE) with high Ag-binding affinity, and also the mature B cell markers 
CD19 and B220 (Ridderstad and Tarlinton 1998). Recent evidence for a CD19
-
 B220
-
 BMem 
population (McHeyzer-Williams, Driver et al. 2001) is controversial (Bell and Gray 2003). It is 
generally thought that BMem recirculate and establish similar frequencies in lymphoid tissues 
throughout the body (Bachmann, Kundig et al. 1994). Although there is some evidence that BMem 
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may preferentially localize at mucosal surfaces (Liu, Barthelemy et al. 1995), this has not been 
fully investigated and may relate to the Ab isotype expressed and the route of immunization 
(Moser and Offit 2001).  
BMem are quiescent, non-Ab-producing cells. It is only upon activation that BMem divide 
and differentiate into plasma cells producing high affinity Abs. Typically, this process is initiated 
in vivo when BMem are exposed to specific Ag in the presence of CD4
+
 T cell help (Vieira and 
Rajewsky 1990). BMem are strong Ag-presenting cells. High affinity surface Ig receptors on BMem 
facilitate Ag capture for presentation to specific CD4
+
 T cells, and the constitutive expression of 
the costimulatory molecules CD80 and CD86 by BMem promotes cognate T-B interaction (Liu, 
Barthelemy et al. 1995). In vitro studies have demonstrated that BMem, but not naïve B cells, 
generate substantial numbers of plasma cells when stimulated with T cell-derived signals such as 
CD40 ligand, IL-2, and IL-10. The presence of specific Ag was not a requirement (Bernasconi, 
Traggiai et al. 2002; Tangye, Avery et al. 2003). Indeed, non-specific methods of BMem 
activation have been used as a basis for assays to determine Ag-specific BMem frequencies 
(Nanan, Heinrich et al. 2001), but the sensitivity of such an approach remains unclear. It has 
recently been suggested that “bystander” BMem may differentiate into plasma cells in response to 
non-specific signals from CD4
+
 T cells activated in the course of normal in vivo immune 
responses (Bernasconi, Traggiai et al. 2002).  
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Characteristics of Plasma cells 
Long-lived antibody-secreting B cells can also be considered part of the memory B cell 
compartment. The long-lived plasma cells (LLPC) are terminally differentiated cells that 
continually produce high-affinity antibody and survive for the life of the mouse in the absence of 
antigen and cell division (Manz, Thiel et al. 1997; Manz, Lohning et al. 1998; Slifka, Antia et al. 
1998). These nondividing cells differ from BMem in many respects. For instance, plasma cells 
down-regulate surface expression of many typical B cell markers, including MHC class II and 
surface Ig (Abney, Cooper et al. 1978; Halper, Fu et al. 1978). These changes indicate that unlike 
memory B cells, mature plasma cells are unlikely to function as antigen presenting cells.  LLPC 
preferentially homes to the bone marrow for their survival. The survival factors could include 
CXCL12, IL-6, B cell-activation factor (BAFF), a proliferation inducing ligand (APRIL), and 
CD44. Recently, the plasma-cell marker CD138 (also known as syndecan-1) was identified as a 
receptor for APRIL that is involved in the homing of plasma cells to the bone marrow. Inhibition 
of BAFF and APRIL, both of which are lignads for the B cell maturation antigen (BCMA) 
receptor, which is expressed by plasma cells (O'Connor, Raman et al. 2004), but not BAFF alone, 
was found to prevent the survival and/or the migration of newly formed plasma cells to the bone 
marrow (Ingold, Zumsteg et al. 2005). In addition to the bone marrow, survival factors for LLPC 
are also expressed in inflamed tissues (Baggiolini 1998; Cassese, Lindenau et al. 2001; 
Muehlinghaus, Cigliano et al. 2005). The presence of interferon-γ (IFN-γ), a hallmark of 
inflamed tissue, increase both the expression of CXCR3 on B cells differentiating into 
plasmablasts and the expression of CXCR3 ligands by cells in the inflamed tissue, indicating that 
IFN-γ might be particularly important for the attraction of plasmablasts to inflamed tissues. 
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When migratory plasmablasts reach the inflamed tissue, they become resident long-lived plasma 
cells, which do not have migratory capacity. It is not clear, however, whether resident plasma 
cell population in inflamed tissues contributes to serum antibody concentration or provides local 
protection as the humoral memory. It also remains to be determined whether the maintenance of 
antibody concentrations that are observed following a primary immune response is due to long 
lived plasma cells generated from activated naïve B cells or whether it results from reactivation 
of specific BMem that were generated in the primary immune response (Blink, Light et al. 2005; 
Dorner and Radbruch 2005).  
 
Quantitation of memory B cells 
Despite the important contribution that a BMem response makes to resistance to infection, 
there have been few quantitative studies of the BMem pool induced by virus infection. Many 
studies of B cell memory have focused on responses to simple haptens or fluorochromes, since 
these molecules can be utilized in cell staining strategies to identify BMem expressing specific, 
high affinity receptors (Schittek and Rajewsky 1990; Ridderstad and Tarlinton 1998; Shimoda, 
Nakamura et al. 2001; Bell and Gray 2003). However, such an approach cannot be applied to 
virus-specific B cells which generally bind poorly defined conformational epitopes. Virus-
specific BMem can be identified by the transfer of immune cells to a recipient animal followed by 
virus challenge (Bachmann, Kundig et al. 1994), but this approach is time consuming, increases 
animal usage, and is only semi-quantitative. Alternatively, virus-specific BMem frequencies can 
be determined by limiting dilution analysis after an in vitro stimulation step to initiate the 
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proliferation and differentiation of BMem into Ab-secreting plasma cells (Nanan, Heinrich et al. 
2001). Slifka and Ahmed (Slifka and Ahmed 1996) optimized this approach by applying the 
ELISPOT assay for the rapid and sensitive detection of plasma cell formation, and used the assay 
to determine the frequencies of BMem generated by lymphocytic choriomeningitis virus infection.  
To use this assay as a reliable and broad method for measuring BMem frequencies, this method has 
to be tested on other virus system. 
 
CONCLUSION 
The purpose of vaccination is to provide protection from disease via induction and recall 
of immunological memory responses. Despite the important contribution that a BMem response 
makes to resistance to infection, there have been few quantitative studies of the BMem pool 
induced by virus infection or vaccination. One commonly held premise is that a live virus 
infection of the respiratory tract is likely to induce the “optimal” BMem pool in terms of providing 
resistance to re-infection. However, no studies have been conducted to provide a quantitative 
basis for this premise. Comparative studies of the nature of the MBC pool induced by live virus 
infection and by different approaches to vaccination are clearly required.  Fundamental questions 
to be addressed include: “How many virus-specific BMem are there?”, “What is their anatomical 
distribution?”, and “What Ab isotypes do they express?” The answers to such questions are 
essential if rational decisions are to be made about the development and optimization of 
vaccination regimens. 
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The work described in this dissertation has been aimed at (i) developing a sensitive and 
reproducible limiting dilution assay (LDA) for measuring influenza-specific BMem frequencies 
and (ii) applying the influenza-specific BMem assay to determine the state of influenza-specific B 
cell memory generated by respiratory tract infection, and also by  different forms of vaccination 
with inactivated virus in a mouse model. We found ASCs and BMem preferentially localize in the 
lung after i.n. infection whereas, there is minimal localization of the components of B cell       
memory in the lung after i.m. vaccination. Thus, we concluded that the lung is a repository of B 
cell memory after influenza infection and must be taken into account in the development of 
effective local vaccines to protect specifically respiratory tract. However, there are many 
remaining questions concerning the functional significance and anatomical location of B cell 
memory in the lung. It is also need to be determined how homing mechanisms and local 
retention of B cell memory is regulated. 
Although these studies have focused on influenza infection and vaccination, it is 
anticipated that the findings will be generally applicable to other viruses that target the 
respiratory tract.  
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Figure 1.  Cytokine interplay in innate and adaptive immunity. Influenza A virus is capable of 
infecting both epithelial cells in respiratory tract and tissue macrophages. Infected epithelial cells 
produce RANTES, MCP-1, IL-8 and type I IFN, whereas macrophages produce various 
chemokines that attract monocytes/macrophages and proinflamatory cytokines such as IL-1, 
TNF-α that are involved in functional maturation of tissue macrophages and dendritic cells.  
Cytokines and chemokins produced following influenza infection lead to massive infiltration of 
leukocytes from the circulation to the lung which is hallmark of the host defense mechanism 
against viral infection. In addition, Matured macrophages and dendritic cells exit the lung 
through lymphatic system and reach regional lymph nodes to initiate adaptive immune response.  
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Table 1.  Links between influenza infection and chemokine/cytokine-mediated 
immunopathogenesis (adapted from  La Gruta, Kedzierska et al. 2007) 
Chemokine/cytokine                  Function Produced by 
IFN-γ 
 
Inhibits viral replication  
Stimulates CTL mediated killing 
Increases MHC I expression 
Activates macrophages and neutrophils 
Promotes T-cell proliferation 
T cells, NK cells 
TNF-α 
 
Direct antiviral effects  
Neutrophil chemoattractant  
Stimulates macrophage phagocytosis and production 
of IL-1  
Increases vascular permeability  
T cells 
Monocytes/macrophages 
Dendritic cells 
Neutrophils 
IL-1 
 
Increases expression of adhesion factors on 
endothelium 
Increases vascular permeability 
Stimulates IL-6 production 
Monocytes/macrophages  
Dendritic cells 
 
IL-6  
Pro-inflammatory cytokine  
Activates T cells  
 
Respiratory epithelium  
T cells 
Monocytes/macrophages 
Dendritic cells 
MIP-1b (CCL4) 
Monocyte, T cell chemoattractant  
Activates neutrophils 
 
Monocytes/macrophages  
Neutrophils 
T cells 
Dendritic cells 
 
MIG (CXCL9)  Monocyte and T-cell chemoattractant  
 
Respiratory epithelium 
Monocytes/macrophages 
 
IP-10 (CXCL10)  Monocyte and T-cell chemoatrractant  
 
Monocytes/macrophages 
T cells 
Respiratory epithelium 
 
RANTES (CCL5)  
Monocyte, T cell, DC chemoattractant  
Activates T cells 
 
T cells  
Respiratory epithelium 
 
IL-8 (CXCL8)  
Neutrophil and T-cell chemoatrractant  
Activates neutrophils  
 
Respiratory epithelium 
Monocytes/macrophages 
Neutrophils 
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Table 2. Mouse immunoglobulin isotypes  
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Chapter 2 
A strategy for selective, CD4+ T cell-independent 
activation of virus-specific memory B cells for 
limiting dilution analysis 
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Research described in this chapter is a modified version of an aticle published in 2006 in Journal 
of immunological methods by Xiaofeng Li, Daisy J. Vanitha, Hye Mee Joo, Yuxia He, Barry T. 
Rouse and Mark Y. Sangster. 
 
Li X, Vanitha DJ, Joo HM, He Y, Rouse BT, Sangster MY. A strategy for selective, CD4
+
 T 
cell-independent activation of virus-specific memory B cells for limiting dilution analysis.  J 
Immunol Methods. 2006 Jun 30;313(1-2):110-8. Copyright © 2006 by Elsevier B.V.  
In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper includes (1) 
planning experiments and data analysis (2) interpretation of the results (3) Compiling and 
interpretation of the literature (4) understanding how results fit with the literature (5) Preparation of 
graphs, figures and tables (6) editing. 
 
Abstract 
Complete characterization of the B cell response to infection or vaccination is dependent 
on accurate quantitation of the memory B cell (BMem) pool. An established method for measuring 
BMem frequencies is limiting dilution analysis based on in vitro stimulation of BMem to divide and 
differentiate into antibody-secreting cells (ASCs). The presence of specific antibody then serves 
to identify cultures positive for precursor BMem. The sensitivity of this approach is critically 
dependent on optimal in vitro BMem activation. To develop a limiting dilution assay (LDA) for 
measuring influenza-specific BMem frequencies, we evaluated strategies for the in vitro 
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stimulation of influenza-specific MBCs. An ELISPOT assay to enumerate influenza-specific IgG 
BMem was used as the readout for BMem activation. Culture of influenza-specific BMem with 
influenza-infected splenocytes was effective for BMem activation, but T cell-associated factors 
were required for optimal LDA sensitivity and clonal expansion of activated BMem. However, 
optimal influenza-specific BMem activation was T cell-independent when BMem were simply 
cultured with -propiolactone (BPL)-inactivated influenza virus particles (BPL-flu). BPL-flu did 
not stimulate naïve B cells to produce influenza-specific IgG, demonstrating that only BMem were 
activated. In addition, BPL-flu acted selectively and only activated influenza-specific BMem, not 
BMem of other specificities. Analysis of influenza-specific BMem frequencies in different 
anatomical locations in influenza-immune mice established that in vitro stimulation with BPL-flu 
provided the basis for a sensitive and reproducible LDA. Extending our studies to the herpes 
simplex virus (HSV) system, we demonstrated that HSV-specific BMem cultured with BPL-
inactivated HSV were selectively activated to IgG secretion in the absence of T cells. Our studies 
identify BPL-inactivated viral particles as a valuable tool for selective, T cell-independent 
activation of virus-specific BMem in vitro. This strategy eliminates the influence of poorly-defined 
T cell-associated factors on BMem frequency determinations.  
 
 Introduction 
The B cell response to infection or vaccination generates antibody-secreting plasma cells 
and a population of antigen-specific memory B cells (BMem). Typically, BMem are long-lived 
products of the germinal center reaction that express high affinity, isotype-switched 
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immunoglobulin receptors and distribute to lymphoid tissues throughout the body (McHeyzer-
Williams and McHeyzer-Williams 2005). Unlike plasma cells, BMem are quiescent, non-
antibody-secreting cells. It is only upon activation that BMem divide and differentiate into 
antibody-secreting cells (ASCs), a process that generally occurs in vivo when BMem encounter 
recall antigen. The activation requirements of BMem are less stringent than those of naïve B cells 
(Yefenof, Sanders et al. 1986), but still remain incompletely understood. In at least some 
experimental systems, BMem activation is dependent on CD4
+
 T cell help (Ochsenbein, 
Pinschewer et al. 2000). 
Quantitative studies of antigen-specific BMem have frequently focused on responses to 
simple haptens, since these molecules can be tagged with fluorochromes for flow cytometric 
identification of BMem expressing specific receptors (Shimoda, Nakamura et al. 2001; Blink, 
Light et al. 2005). Recently, biotinylated influenza virus hemagglutinin was used to enumerate 
hemagglutinin-specific B cells by flow cytometry (Doucett, Gerhard et al. 2005). The analysis of 
antigen-specific B cells by flow cytometry has obvious appeal, but currently this approach 
provides an incomplete picture of the BMem pool generated by many pathogens. The B cell 
response to pathogens is generally complex, being directed against multiple, often poorly-
defined epitopes on multiple molecules. 
An alternative approach to BMem quantitation that may better accommodate the diverse B 
cell response to pathogens is the limiting dilution assay (LDA). This assay is based on the in 
vitro stimulation of BMem to divide and differentiate into ASCs, with the presence of specific 
antibody serving to identify cultures positive for precursor BMem. The period required for BMem 
stimulation can be minimized by applying an ELISPOT assay to directly detect antibody-
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secreting daughter cells (Slifka and Ahmed 1996). A key requirement for accurate MBC 
quantitation by LDA is effective in vitro BMem activation. One approach is to non-specifically 
activate B cells with polyclonal stimulators (Nanan, Heinrich et al. 2001; Crotty, Aubert et al. 
2004), but massive cell proliferation and antibody production are likely to have detrimental 
effects on culture conditions and assays for specific antibody. Alternatively, a more selective 
activation of BMem may be achieved by incubation with appropriate antigenic forms (Hebeis, 
Klenovsek et al. 2004) . Virus-specific MBCs have been activated by culture with virus-infected 
cells or purified viral particles (Jones and Ada 1987; Slifka and Ahmed 1996; Moser and Offit 
2001), but the in vitro culture conditions required for optimal BMem activation and clonal 
expansion are not well defined. 
The BMem response to a previously encountered virus contributes substantially to immune 
protection, and is likely to be a key determinant of the effectiveness of inactivated viral vaccines 
that target the humoral arm of the immune system. It is therefore surprising that little quantitative 
information on the BMem pool induced by viral infection or vaccination has been collected. 
Notably, Slifka and Ahmed used a limiting dilution approach to determine lymphocytic 
choriomeningitis virus (LCMV)-specific BMem frequencies. In vitro BMem activation was 
achieved by incubation with splenocytes from LCMV carrier mice, a cell population heavily 
infected with the virus. Supplementation of stimulation cultures with ConA-conditioned medium 
increased LCMV-specific MBC frequencies, indicating a requirement for T cell-derived factors 
(Slifka and Ahmed 1996).       
The current report describes the development of a limiting dilution assay for determining 
influenza virus-specific BMem frequencies in a mouse model. Our initial strategy of using 
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influenza virus-infected splenocytes to activate specific BMem required T cell-associated factors 
for optimal effectiveness. However, the use of -propiolactone (BPL)-inactivated influenza virus 
particles achieved T cell-independent BMem activation. Extension of our studies to a mouse 
model of herpes simplex virus (HSV) infection demonstrated that BPL-inactivated HSV particles 
activated HSV-specific BMem  in the absence of T cells. Our findings identify a simple, broadly 
applicable strategy for in vitro activation of virus-specific BMem for limiting dilution analysis. 
Using this strategy, the proportion of CD4
+
 T cells present in culture is unlikely to be a factor in 
BMem activation, and any detrimental effects of viral replication on leukocyte function are 
eliminated. 
 
 Materials and Methods 
Mice 
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice 
were housed under specific pathogen-free conditions until infection, and thereafter in BSL2 
containment. Female mice were used in all studies and were infected at 8-10 wk of age. The 
Animal Care and Use Committee of the University of Tennessee approved all animal procedures. 
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 Viruses 
Influenza virus A/HKx31 (H3N2) grown and titrated in the allantoic cavity of 
embryonated hen’s eggs was obtained from Dr. P. C. Doherty (St. Jude Children’s Research 
Hospital, Memphis, TN). The KOS strain of HSV-1 was grown and plaqued in Vero cells. HSV 
was concentrated from clarified tissue culture grown virus by centrifugation at 75,000g for 1h. 
For HSV inactivation by BPL treatment, concentrated virus in 0.1% BPL (Acros Organics), 0.1 
M Tris-HCl (pH 7.5) was incubated for 2 h at 37°C with frequent mixing, and then held 
overnight at 4°C. Complete inactivation was confirmed by the absence of cytopathic effect in 
Vero cell monolayers inoculated with the treated virus. Preparations of sucrose gradient-purified 
and BPL-inactivated influenza A/HKx31 were purchased from Charles River (Wilmington, MA). 
Viral protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad, 
Hercules, CA). All virus preparations were stored at -80°C. 
 
Infection and sampling 
Mice were anesthetized with Avertin (2,2,2-tribromoethanol) given intraperitoneally, and 
then infected intranasally with 10
6.8 
50% egg infectious doses of influenza virus (30 l in PBS). 
Influenza-immune mice were sampled 60-90 days after infection. Mice were infected 
intraperitoneally with 10
6
 PFU of HSV, and sampled 30-45 days after infection. The right 
posterior mediastinal lymph node (MLN), inguinal lymph nodes (ILN), and spleen were 
collected and gently disrupted to generate single cell suspensions. Splenocytes were cleared of 
erythrocytes by ammonium chloride lysis. Nasal-associated lymphoid tissue (NALT) was 
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collected attached to the palate (Asanuma, Thompson et al. 1997) and cells were released by 
teasing. 
 
 Memory B cell assay 
Single-cell suspensions of immune cells were prepared in IMDM (Invitrogen, Carlsbad, 
CA) containing L-glutamine (2 mM), sodium pyruvate (1 mM), penicillin (100 IU/ml), 
streptomycin (100 g/ml), gentamicin (10 g/ml), and 5 x 10
-5
 M -mercaptoethanol (designated 
B cell medium, BCM), and supplemented with 10% fetal bovine serum (FBS). Initially, immune 
cells were stimulated in vitro by culture with virus-infected splenocytes. Two-fold dilutions of 
immune cells (12 wells per dilution) were incubated in 96-well flat-bottom tissue culture plates 
(Corning) containing 5 x 10
5
 irradiated (3,000 rad) syngeneic naïve spleen cell feeders and 5 x 
10
5
 irradiated (3,000 rad) syngeneic virus-infected splenocytes. The total volume per well was 
200 l. Plates were incubated for 4 days (routinely) at 37°C in a humidified atmosphere 
containing 5% CO2. After incubation, cells in each well were washed 3 times as described 
previously (Slifka and Ahmed 1996). Briefly, this involved removing a volume of supernatant, 
adding fresh BCM containing 2% FBS, and pelleting the cells by centrifugation. After the final 
wash, cells in each well were resuspended in the remaining volume of medium and transferred to 
antigen-coated plates for enumeration of virus-specific ASCs by ELISPOT assay (described 
below). Pre-existing virus-specific ASC numbers in immune cell populations at the time of 
sampling were determined by direct ex vivo ELISPOT assay. After in vitro BMem activation and 
ELISPOT analysis, individual wells were scored positive for virus-specific BMem if progeny ASC 
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numbers were greater than the mean pre-existing ASC number plus 3 standard deviations. A 
minimum of 6 progeny ASCs were also required for a well to be scored positive. In an 
alternative strategy, graded doses of immune cells were stimulated in vitro by culture with 10
6
 
irradiated (3,000 rad) syngeneic naïve spleen cell feeders plus BPL-inactivated viral particles 
(generally. 0.05-0.1 g/well). On occasion, mitomycin C treatment (Slifka and Ahmed 1996) 
was used instead of irradiation to block proliferation of naïve spleen cell feeders. Otherwise, the 
BMem assay was performed as described above. The virus-specific BMem frequency was calculated 
from the number of negative wells per cell dilution by extrapolation to the dilution that gave 37% 
negative wells (Topham and Doherty 1998). In some experiments, in vitro stimulation cultures 
were supplemented with 10
5
 CD4
+
 T cells enriched from the spleens of immune mice by 
negative selection to >85% purity (Topham and Doherty 1998). Briefly, immune splenocytes 
treated with anti-MHC class II (TIB-120) and anti-CD8 (53-6.72) were incubated with sheep 
anti-mouse and sheep anti-rat Ig-coupled Dynabeads (Invitrogen), and a magnet was applied 
according to the manufacturer’s instructions to remove labeled cells. Input cell volumes in the 
BMem assay were adjusted to maintain the total volume per well at 200 l. T cell-depleted 
immune splenocytes (<1% CD3
+
 T cells) were prepared by complement lysis of cells coated with 
anti-Thy-1.2 mAb (AT83). Splenocytes were depleted of CD19
+
 B cells (<0.6%) by treatment 
with biotinylated anti-CD19 mAb (1D3; BD Biosciences, San Diego, CA), 1 g/10
6
 cells, 
followed by incubation with streptavidin-coupled Dynabeads (Invitrogen), and magnetic removal 
of labeled cells according to the manufacturer’s instructions. Cell populations were characterized 
by flow cytometry using FITC-conjugated mAbs to CD3  (145-2C11) and CD4 (RM4-5); PE-
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conjugated mAbs to CD8  (53-6.7) and CD19 (1D3); and APC-conjugated anti-CD3  mAb 
(145-2C11; BD Biosciences) as staining reagents. 
 
 Influenza-infected splenocytes 
Up to 10
8
 erythrocyte-free naïve splenocytes in HBSS were pelleted and resuspended in 1 
ml HBSS. Influenza virus stock was added to give the required multiplicity of infection, and the 
preparation was incubated for a total of 4 h with occasional mixing in a 37°C waterbath. After 1 
h of the incubation period, 10 ml BCM containing 10% FBS was added per ml of cell suspension. 
The infected cells were then irradiated (3,000 rad), washed once, and resuspended in complete 
BCM. 
 
 ELISPOT assay 
The ELISPOT assay was adapted to enumerate influenza-specific or HSV-specific IgG 
ASCs. A preparation of concentrated viral particles was disrupted for 10 min at room 
temperature in a 1 in 10 dilution of disruption buffer (0.5% Triton X-100, 0.6 M KCl, and 0.05 
M Tris-HCl, pH 7.5) in PBS, further diluted in PBS, and plated at 1 g/well in nitrocellulose-
bottomed 96-well Multiscreen HA filtration plates (Millipore, Bedford, MA). After overnight 
incubation at 4°C, plates were washed with PBS, and blocked with BCM containing 10% FBS. 
Plates were emptied by flicking, and cell suspensions (including resuspended cells from 96-well 
MBC assay plates) were added in volumes of approximately 100 l/well. After incubation for 3-
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4 h at 37°C in a humidified atmosphere containing 5% CO2, plates were thoroughly washed with 
PBS alone and PBS containing 0.1% Tween 20. Alkaline phosphatase-conjugated goat anti-
mouse IgG (Southern Biotechnology, Birmingham, AL) diluted to 2 g/ml in PBS containing 5% 
bovine serum albumin was added (100 l/well), and the plates were incubated overnight at 4°C. 
The plates were then washed extensively with PBS alone and PBS containing 0.1% Tween 20, 
including washing the underside of the nitrocellulose filters. Spots were developed at room 
temperature by the addition of 1 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (Sigma, St. 
Louis, MO) in diethanolamine buffer (10% diethanolamine, 0.1 M NaCl, 5 mM MgCl2, and 0.1 
M Tris-HCl, pH 9.5), 100 l/well. After optimal spot development, plates were washed with PBS 
and dried, and spots representing individual ASCs were counted using an Olympus SZX9 
stereozoom microscope. 
 
Statistics 
Statistical comparisons of mean values were performed using the nonparametric Mann-
Whitney U test for unpaired samples.       
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Results 
In vitro activation of influenza virus-specific BMem using virus-infected splenocytes 
Our primary goal of determining influenza-specific BMem frequencies by limiting dilution 
assay required an effective method for the in vitro activation of influenza-specific BMem. Initial 
experiments evaluated the use of irradiated, influenza-infected syngeneic splenocytes as 
“stimulators” for this purpose, since a similar approach activates BMem in the LCMV system 
(Slifka and Ahmed 1996). In addition, virus-infected splenocytes stimulate the activation of 
primed, influenza-specific CD4
+
 T cells, and these would be expected to contribute cytokines to 
the cultures (Sarawar and Doherty 1994). Limiting, two-fold dilutions of spleen cells from 
influenza immune mice (the source of BMem) were cultured in 96-well plates with virus-infected 
stimulator cells. The starting input dose of immune spleen cells was 10
5
. After 4 days incubation, 
cells were resuspended and transferred to influenza-coated, 96-well ELISPOT plates for the 
enumeration of influenza-specific ASCs. For each input dose of immune cells, post-stimulation 
ASC numbers were compared to the number of pre-existing influenza-specific ASCs in the 
immune spleen, determined by ELISPOT assay at the time of sampling. Wells were scored as 
positive for influenza-specific BMem if the post-stimulation ASC count was greater than the mean 
background count plus 3 SD. All post-stimulation ASC counts of ≤5 were considered negative. 
The influenza-specific BMem frequency was calculated from the number of negative wells per cell 
dilution by extrapolation to the dilution that gave 37% negative wells (Topham and Doherty 
1998). Studies of the LCMV system by Slifka and Ahmed validated the ELISPOT-based limiting 
dilution assay for quantitation of virus-specific BMem (Slifka and Ahmed 1996). 
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Influenza virus is completely cleared from sublethally infected mice by 10-12 days after 
infection, corresponding to a decrease in the number of influenza-specific ASCs in responding 
lymphoid tissue (Liang, Hyland et al. 2001). By 8 weeks or more after infection, the mean 
number of influenza-specific IgG ASCs in the spleen at an input dose of 10
5
 immune cells was 
<10. In contrast, stimulation of the same input dose of cells with virus-infected splenocytes 
typically generated uncountable (>100) influenza-specific IgG ASCs. No influenza-specific IgG 
ASCs were detected after in vitro stimulation of splenocytes from naïve mice, demonstrating that 
the ASCs generated by stimulation of immune splenocytes reflected activation of virus-specific 
BMem. 
Influenza-specific BMem frequencies were determined after in vitro stimulation with virus-
infected splenocytes prepared using a range of multiplicities of infection (MOIs). Highest 
frequencies were obtained at MOIs ranging from 0.01–1.0 (Table I), and an MOI of 0.1 was 
selected for subsequent experiments using virus-infected splenocytes. 
An important question concerned the requirement for CD4
+
 T cell help for optimal in 
vitro BMem activation. To evaluate the contribution of T cells, we determined influenza-specific 
BMem frequencies using total or T cell-depleted immune splenocytes. Results were standardized 
by expressing the BMem frequency for CD19
+
 cells. Depletion of CD19
+
 cells to <0.6% 
eliminated influenza-specific BMem from immune splenocytes (data not shown), indicating that 
BMem reside in the CD19
+
 population (Bell and Gray 2003; Blink, Light et al. 2005). The use of 
total immune splenocytes gave up to three-fold higher frequencies than did the T cell-depleted 
populations (Table II), indicating an important role for T cell-associated factors during in vitro 
stimulation. Although the key T cell-associated factors in this system have not been defined, it is 
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likely that they are derived primarily from CD4
+
 T cells (Sarawar and Doherty 1994). To 
determine whether CD4
+
 T cell help was limiting even during stimulation of total immune 
splenocytes, a cell population that contained approximately 20% CD4
+
 T cells, we evaluated the 
effect of supplementing the stimulation cultures with enriched CD4
+
 T cells from influenza-
immune mice. Addition of enriched, immune CD4
+
 T cells (10
5
 cells/well; >85% CD4
+
 T cells) 
to total immune splenocytes cultured with virus-infected stimulator splenocytes had little effect 
on the number of wells scored positive for BMem (and hence the BMem frequency), but increased 
the number of ASCs generated in positive wells (data not shown). Taken together, our findings 
indicate that CD4
+
 T cell-derived factors promote the activation and clonal expansion of 
influenza-specific BMem during in vitro culture with virus-infected splenocytes. 
 
In vitro activation of influenza virus-specific BMem using BPL-inactivated virus particles 
Recently, Hebeis and colleagues demonstrated that the form of challenge antigen 
determines the CD4
+
 T cell dependence of BMem responses. The in vivo BMem response elicited 
by antigen in the form of non-replicating, virus-like particles was CD4
+
 T cell-independent, 
whereas that elicited by soluble monomeric antigen was not (Hebeis, Klenovsek et al. 2004). 
Apparently, the repetitive arrangement of antigens on the virus-like particles provided a potent 
activating signal for BMem that circumvented the requirement for CD4
+
 T cell help. We therefore 
tested whether BPL-inactivated influenza virus particles (BPL-flu) would effectively activate 
virus-specific BMem in vitro for limiting dilution analysis. Graded doses of immune splenocytes 
were simply cultured with a feeder population of irradiated naïve syngeneic splenocytes to which 
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BPL-flu had been added. Titration of the input amount of BPL-flu established that effective 
influenza-specific BMem activation was achieved with as little as 0.01 g/well (Fig. 1A). BPL-flu 
was used at 0.1 g/well in subsequent experiments. BMem frequencies were similar after in vitro 
stimulation of immune cells with BPL-flu for periods of 3, 4, or 5 days (data not shown), and an 
incubation period of 4 days was used routinely. No influenza-specific IgG ASCs were generated 
during the incubation of splenocytes from naïve mice with BPL-flu, demonstrating that only 
BMem are activated. BMem frequencies were comparable when total immune splenocytes were 
stimulated in vitro with BPL-flu or with virus-infected splenocytes (Table III). However, a 
consistent trend was for higher ASC counts in positive wells after BPL-flu stimulation, 
indicating that this approach generated greater clonal expansion of BMem. 
We next evaluated the requirement for CD4
+
 T cells during in vitro BMem activation with 
BPL-flu. T cell-depleted splenocytes were stimulated with BPL-flu, or with virus-infected 
splenocytes supplemented with enriched, immune CD4
+
 T cells to provide optimal BMem 
activation. In two separate experiments, stimulation with BPL-flu produced BMem frequencies 
similar to those obtained using virus-infected stimulators plus immune CD4
+
 T cells, and 
approximately 2.4-fold greater than those obtained by stimulation with virus-infected 
splenocytes alone (Table IV). In addition, stimulation with BPL-flu or with virus-infected 
splenocytes plus immune CD4
+
 T cells resulted in similar clonal expansion of BMem, as indicated 
by the number of ASCs generated in positive wells (Fig. 2). These experiments emphasize the 
contribution of CD4
+
 T cell-associated factors to in vitro BMem activation. Importantly, our 
findings indicate that BPL-flu effectively activates influenza-specific BMem in vitro in the 
absence of CD4
+
 T cells. 
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To assess the specificity of BPL-flu in the activation of BMem, we cultured splenocytes 
from HSV-immune mice with BPL-flu. No HSV-specific ASCs were generated in these cultures, 
demonstrating that BPL-flu activates only influenza-specific BMem (Fig. 1B). LPS was below the 
level of detection at the BPL-flu concentrations used for activating influenza-specific BMem. 
 
Measurement of influenza-specific BMem frequencies in different anatomical locations 
We next determined whether in vitro stimulation with BPL-flu provided the basis for a 
sensitive limiting dilution assay to measure influenza-specific BMem frequencies in different 
anatomical locations. Cell populations for analysis were prepared from the NALT, MLN, spleen, 
and ILN of mice 8-12 weeks after i.n. influenza infection. The tissues sampled included sites 
(NALT, MLN) that generate strong B cell responses to influenza infection of the respiratory tract 
(Liang, Hyland et al. 2001; Sangster, Riberdy et al. 2003), and a site (ILN) that does not. Our 
analysis demonstrated influenza-specific BMem in all sites examined (Fig. 3), supporting the 
notion that BMem distribute to lymphoid tissues throughout the body (Bachmann, Kundig et al. 
1994). However, this distribution was not equal. Significantly higher BMem frequencies were 
present in the NALT and MLN compared with the spleen and ILN, indicating a concentration of 
BMem in lymphoid tissue associated with the site of infection even long after the infectious agent 
has been cleared. This preliminary analysis establishes that our approach is sufficiently sensitive 
and reproducible to demonstrate differences between anatomical locations in influenza-specific 
BMem frequencies.   
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BPL-inactivated HSV activates HSV-specific BMem for limiting dilution analysis 
Our studies of the influenza system raised the possibility that the use of BPL-inactivated 
virus particles may have broad applicability for in vitro BMem activation. We therefore turned to a 
mouse model of HSV infection and analyzed approaches to the in vitro activation of HSV-
specific BMem for limiting dilution analysis. An ELISPOT assay for HSV-specific IgG ASCs was 
used to detect BMem activation and plasma cell formation. Splenocytes from HSV-immune mice 
(the source of BMem) were cultured in limiting dilution format with feeder splenocytes to which 
BPL-inactivated HSV (BPL-HSV) had been added. This strategy effectively activated HSV-
specific BMem at BPL-HSV doses as low as 0.0025 g/well (Fig. 1B). No HSV-specific IgG 
ASCs were generated from naïve splenocytes stimulated with BPL-HSV, demonstrating that 
only BMem were activated. The specificity of BPL-HSV stimulation was tested by incubating 
splenocytes from influenza-immune mice with BPL-HSV. No influenza-specific ASCs were 
generated in these cultures, demonstrating that BMem activation by BPL-HSV is antigen specific 
(Fig. 1A). LPS was undetectable in the BPL-HSV preparation. 
To evaluate the requirement for T cells during in vitro BMem activation by BPL-HSV, 
intact or T cell-depleted immune splenocytes were incubated in limiting dilution format with 
irradiated feeder splenocytes plus BPL-HSV. HSV-specific MBC frequencies (adjusted to 
accommodate differences in the proportion of CD19
+
 input cells) were similar for the intact and 
T cell-depleted immune populations (Table V). Our findings indicate that BPL-HSV (like BPL-
flu in the influenza system) effectively activates virus-specific BMem in vitro in the absence of T 
cell-associated factors. 
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 Discussion 
The measurement of virus-specific BMem frequencies by limiting dilution analysis 
typically relies on BMem activation and differentiation during a period of in vitro stimulation. 
Cultures are then scored as positive or negative for virus-specific BMem on the basis of specific 
antibody secretion. In this report, we describe a strategy utilizing BPL-inactivated virus particles 
for the in vitro activation of virus-specific BMem. This strategy selectively activates virus-specific 
BMem and, importantly, achieves this without a requirement for CD4
+
 T cell-associated factors. 
It is well-established that BMem have less stringent activation requirements than do naïve 
B cells. In fact, this is reflected in the limiting dilution assay described in this report, since only 
B cells from immune mice, but not from naïve mice, were stimulated in vitro to produce virus-
specific antibodies. However, the requirements for optimal BMem activation in vitro are not 
known. Initially, we used virus-infected splenocytes as “stimulators” for the activation of 
influenza-specific BMem. This approach produced consistently higher influenza-specific BMem 
frequencies when total, compared with T cell-depleted, immune splenocytes were tested. 
Supplementation of total immune splenocytes with enriched immune CD4
+
 T cells had no effect 
on the influenza-specific BMem frequency, but did increase the number of ASCs generated in 
positive wells. Thus, when influenza-infected splenocytes were used as stimulators, there was a 
minimum requirement for T cell-associated factors to promote BMem activation and plasma cell 
formation. Exceeding this minimum requirement by adding immune CD4
+
 T cells simply 
increased the number of plasma cells formed, presumably by driving the clonal expansion of 
activated BMem. Although the precise nature of the T cell “help” remains to be determined, T 
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cell-derived cytokines are likely to be important factors. In studies of the LCMV system, BMem 
activation during culture with virus-infected splenocytes was improved by supplementary 
cytokines (Slifka and Ahmed 1996). 
Our studies demonstrate that in vitro BMem activation with BPL-inactivated virus particles, 
at least in the influenza and HSV systems, circumvents the requirement for T cell-associated 
factors. This strategy provides the basis for a limiting dilution assay that can be applied with 
confidence to determine BMem frequencies in lymphoid populations that differ substantially in the 
proportion of CD4
+
 T cells. For instance, in our analysis of influenza-specific BMem frequencies 
in different anatomical locations, the percentage (mean±SD) of CD4
+
 T cells in the tissues 
sampled were 5.6±0.3 (NALT), 20.1±1.6 (spleen), 23.6±0.9 (MLN), and 31.7±2.6 (ILN). The 
use of BPL-flu for in vitro BMem activation minimized the possibility that results would be 
influenced by the proportion of CD4
+
 T cells present in the cultures. 
Recently, Hebeis and colleagues emphasized the importance of antigen form in the 
induction of CD4
+
 T cell-independent BMem responses in vivo (Hebeis, Klenovsek et al. 2004). 
The effectiveness of BPL-inactivated particles in our studies may be due to repetitively arranged 
epitopes that cross-link B cell receptors and generate potent activating signals. If this is the case, 
then the BMem activated will only be those specific for epitopes displayed by molecules on the 
surface of virions. Generally, however, the most reactive B cell determinants are those present on 
the abundant viral surface glycoproteins, and it is these determinants that are the targets of 
neutralizing antibody responses. The majority of influenza-specific antibodies generated during 
infection, including the primary protective antibodies, target the hemagglutinin and 
neuraminidase envelope glycoproteins (Marshall, Sealy et al. 1999). It remains to be determined 
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whether culture with BPL-flu activates the same or a more restricted set of BMem specificities 
than does culture with influenza-infected splenocytes. The effectiveness of BPL-inactivated viral 
particles as BMem activators raises the possibility that antigens appropriately arranged on an 
artificial lipid vesicle (Huckriede, Bungener et al. 2003) may also be used for in vitro BMem 
activation. This strategy may permit the activation of BMem specific for selected molecules. 
Numerous strategies for viral inactivation may generate particles that are suitable for in 
vitro BMem activation. An important consideration is the need to achieve viral inactivation with 
minimal modification of B cell epitopes. In the current study, viral inactivation was achieved by 
treatment with BPL, a potent alkylating agent that acts primarily through modification of the 
viral genome (Perrin and Morgeaux 1995). Compared with other methods of viral inactivation, 
BPL treatment completely inhibits replicative capacity with much less severe effects on protein 
structure (Sangster, Mo et al. 1997). 
In summary, this report describes a simple, inexpensive strategy for selective, virus-
specific BMem activation in vitro. Most importantly, BMem activation and clonal expansion is 
achieved independently of poorly-defined CD4
+
 T cell-associated factors, thus eliminating a 
variable that adds uncertainty to estimates of BMem frequencies. In addition, the use of inactivated 
virus particles for BMem activation avoids problems that may be caused by live virus. Although 
this may not be a significant concern with influenza virus, many viruses including HSV induce 
the functional impairment or death of leukocytes infected in vitro (Brucher, Domke et al. 1984; 
Jones, Fernandez et al. 2003). The fact that only antigen-specific BMem are activated avoids the 
extensive cell proliferation and detrimental effects on cell culture conditions associated with the 
use of polyclonal B cell activators. This makes the strategy particularly suitable for limiting 
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dilution assays performed in 96-well plates and requiring incubation for three or more days. 
Finally, our demonstration that the strategy is effective with both influenza virus and HSV 
suggests that it is likely to have broad applicability in a wide range of viral systems. 
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Table I  
Influenza-specific BMem frequencies determined after in vitro stimulation 
with virus-infected splenocytes prepared using different multiplicities of 
infection
a
 
MOI BMem Frequency
b
 
5 1.4 x 10
4
 
1 8.8 x 10
3
 
0.1 8.2 x 10
3
 
0.01 7.7 x 10
3
 
0.001 2.3 x 10
4
 
  
a
 Total splenocytes from influenza-immune mice were incubated in limiting  
  dilution format with influenza-infected syngeneic splenocytes. 
b
 Numbers represent the reciprocal of calculated influenza-specific BMem 
  frequencies per total splenocytes. Results are representative of two  
  separate experiments. 
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Table II    
Comparison of influenza-specific BMem frequencies determined using total or  
T cell-depleted immune splenocytes
a
 
Immune splenocytes 
BMem Frequency
b
 
Spleen 1 Spleen 2 Spleen 3  
Total 1.3 x 10
4                                 
 1.6 x 10
4  
                                    5.8 x 10
3
 
T cell-depleted 4.0 x 10
4                                   
 2.8 x 10
4  
                                  8.3 x 10
3
 
    
a
 Total or T cell-depleted splenocytes from influenza-immune mice were incubated   
   in limiting dilution format with influenza-infected syngeneic splenocytes.  
b
 Numbers represent the reciprocal of calculated influenza-specific BMem frequencies 
  per CD19
+
 splenocytes. 
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Table  III 
Influenza-specific BMem frequencies determined after in vitro stimulation with   
virus-infected splenocytes or BPL-flu 
In vitro stimulation
a
 
BMem Frequency
b                                                                         
   
Experiment 1 Experiment 2 Experiment 3 
Virus-infected splenocytes 7.1 x 10
3                                                   
 
                                           
 7.3 x 10
3
   8.2 x 10
3
   
BPL-flu 8.3 x 10
3                                                 
 7.1 x 10
3
5.6 x 10
3
 
    
a
 Total splenocytes from influenza-immune mice were cultured in limiting dilution   
  format, together with either influenza-infected syngeneic splenocytes or BPL-flu.  
b
 Numbers represent the reciprocal of calculated influenza-specific BMem frequencies 
  per total splenocytes. 
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Table  IV    
In vitro stimulation with BPL-flu activates influenza-specific BMem in the absence of  
CD4
+
 T cells 
In vitro stimulation
a
 CD4
+
 T cells
b
 
 BMem Frequency
c
 
Experiment 1 Experiment 2 
Virus-infected splenocytes - 8.3 x 10
3                                                   
 
                                           
 1.1 x 10
4
   
Virus-infected splenocytes + 4.3 x 10
3                                                    
 4.5 x 10
3
 
BPL-flu - 3.4 x 10
3                                                 
 4.1 x 10
3
    
a
 T cell-depleted splenocytes from influenza-immune mice were cultured in limiting   
  dilution format, together with either influenza-infected syngeneic splenocytes or  
  BPL-flu. 
b 
Cultures were supplemented as indicated with enriched CD4
+
 T cells from the spleens    
  of influenza-immune mice (10
5
 cells/well; >85% CD4
+
 T cells; <0.1% CD8
+
 T cells).    
  Control cultures established that this population was free of influenza-specific BMem. 
c
 Numbers represent the reciprocal of calculated influenza-specific MBC frequencies  
  per CD19
+
 splenocytes. 
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Table V 
Comparison of HSV-specific BMem frequencies determined using total 
or T cell-depleted immune splenocytes
a
 
Immune splenocytes 
BMem Frequency
b
 
Spleen 1 Spleen 2 
Total 4.1 x 10
3                                 
 8.7 x 10
3  
                                    
T cell-depleted 4.0 x 10
3                                   
 1.0 x 10
4  
                                  
   
a
 Total or T cell-depleted splenocytes from HSV-immune mice were   
   incubated in limiting dilution format with BPL-HSV (0.01 g/well).  
b
 Numbers represent the reciprocal of calculated HSV-specific BMem 
  frequencies per CD19
+
 splenocytes. 
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Figure 1. Titration of BPL-inactivated viral particles for in vitro BMem activation. (A) Influenza-
specific BMem frequencies determined after in vitro stimulation with different doses of BPL-flu. 
Total splenocytes from influenza-immune mice were incubated in limiting dilution format with 
irradiated syngeneic splenocytes and different doses of BPL-flu. Parallel sets of control wells 
received BPL-HSV instead of BPL-flu. After 4 days incubation, influenza-specific ASC numbers 
were determined by ELISPOT assay, and wells were scored as positive or negative for precursor 
BMem. Numbers represent the reciprocal of calculated influenza-specific BMem frequencies per 
total splenocytes. No influenza-specific ASCs were generated in wells that contained 0.1, 0.01, 
or 0.005 g/well of BPL-HSV.  Results are representative of two separate experiments. (B) 
HSV-specific BMem frequencies determined after in vitro stimulation with different doses of 
BPL-HSV. HSV-specific BMem frequencies were determined as described above using total 
splenocytes from HSV-immune mice and a range of doses of BPL-HSV. Control wells received 
BPL-flu instead of BPL-HSV. An ELISPOT assay for HSV-specific ASCs was used to score 
wells as positive or negative for precursor BMem. Numbers represent the reciprocal of calculated 
HSV-specific BMem frequencies per total splenocytes. No HSV-specific ASCs were generated in 
wells that contained 0.1, 0.01, or 0.005 g/well of BPL-flu.  Results are representative of two 
separate experiments.   
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Figure 2. Clonal expansion of influenza-specific BMem after in vitro stimulation. Two-fold 
dilutions of T cell-depleted splenocytes from influenza-immune mice (12 wells per dilution) 
were stimulated in vitro by culture with (i) influenza-infected splenocytes, (ii) influenza-infected 
splenocytes plus enriched CD4
+
 T cells from the spleens of influenza immune mice, or (iii) BPL-
flu. After 4 days incubation, influenza-specific ASC numbers in each well were determined by 
ELISPOT assay. ASC numbers are shown for wells receiving 5 x 10
4
 T cell-depleted splenocytes. 
A horizontal bar identifies the mean. Results are representative of two separate experiments. *, P 
< 0.0005 compared with cultures stimulated with influenza-infected splenocytes alone. 
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Figure 3. Influenza-specific BMem frequencies in different anatomical locations. Cell populations 
from influenza-immune mice were cultured for 4 days in limiting dilution format, together with 
BPL-flu for in vitro stimulation. An ELISPOT assay for influenza-specific ASCs was used to 
identify wells positive for precursor BMem, and BMem frequencies were calculated. Numbers 
represent the reciprocal of influenza-specific BMem frequencies per total input cells. A horizontal 
bar identifies the mean. *, P < 0.02 compared with NALT and MLN.   
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Chapter 3 
Broad dispersion and lung localization of virus-
specific memory B cells induced by influenza 
pneumonia 
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Research described in this chapter is a modified version of an aticle published in 2008 in the 
National Academy of Sciences of the USA by Hye Mee Joo, Yuxia He and Mark Y. Sangster. 
 
Joo HM, He Y, Sangster MY. Broad dispersion and lung localization of virus-specific memory B 
cells induced by influenza pneumonia. Proc Natl Acad Sci U S A. 2008 March 4; 105(9): 3485–
3490. Copyright © 2008 by The National Academy of Sciences of the USA 
In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper includes 
(1) the majority of the lab work and (2) most of planning experiments and the data analysis and 
(3) Preparation of graphs, figures and tables and (4) editing and discussions. 
 
ABSTRACT 
Although memory B cells (BMem) contribute significantly to resistance to infection, BMem 
population characteristics that may relate to protective efficacy have received little attention. 
Here we report a comprehensive quantitative analysis of virus-specific IgG and IgA BMem 
dispersion following transient influenza pneumonia in mice. From early in the response, BMem 
circulated continuously and dispersed widely to secondary lymphoid tissues. However, a 
complicated picture emerged with BMem frequency differences between secondary lymphoid 
tissues indicating an influence of local tissue factors on trafficking. BMem numbers increased and 
stabilized at tissue-specific frequencies without contraction of the BMem pool during the period of 
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analysis. The lung was notable as a non-secondary lymphoid tissue where a rapid influx of IgG 
and IgA BMem established relatively high frequencies that were maintained long-term. Our 
findings provide insights into the pattern of BMem dispersion, and emphasize the lung as a 
complex repository of immune memory following local infection. 
 
INTRODUCTION 
Memory B and T cell subsets generated during adaptive immune responses play a key 
role in long-term resistance to infectious agents expressing previously encountered antigens. 
After formation in organized secondary lymphoid tissues, the cellular elements of immunological 
memory migrate via function-related trafficking pathways and populate lymphoid and non-
lymphoid tissues throughout the body. This process establishes a dispersed state of cellular 
memory that optimizes protective efficacy. The dispersed CD4 and CD8 memory T cell 
populations have been well-characterized (Marshall, Turner et al. 2001; Masopust, Vezys et al. 
2001; Reinhardt, Khoruts et al. 2001), but similar comprehensive studies of B cell memory have 
not been performed (Anderson, Tomayko et al. 2006). 
The two cellular components of B cell memory, long-lived plasma cells (LLPCs) and 
memory B cells (BMem), are the products of germinal center reactions in secondary lymphoid 
tissue (McHeyzer-Williams and McHeyzer-Williams 2005). LLPCs are classically recognized as 
Ab-secreting cells (ASCs) that localize in the bone marrow (BM) and maintain circulating Ab 
levels (Slifka and Ahmed 1996). However, long-lasting populations of IgA-secreting cells (in 
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particular) are also established at mucosal surfaces after mucosal immunization where they 
provide local protection (Jones and Ada 1986; Liang, Hyland et al. 2001). In contrast to plasma 
cells, BMem are quiescent cells that require stimulation to divide and differentiate into ASCs. 
Upon encounter with recall antigen, BMem mediate the rapid, vigorous, and high affinity 
secondary Ab response that plays a key role in immune protection. The impression from studies 
to date is that BMem spread widely to organized lymphoid tissues (Bachmann, Kundig et al. 1994; 
Slifka, Antia et al. 1998; Vanitha, Joo et al. 2007), but the full extent of BMem dispersion has not 
been determined. It is also unclear whether BMem trafficking patterns relate to the Ab isotype 
expressed. 
The present study provides a comprehensive quantitative analysis of the dispersed 
cellular components of B cell memory induced by influenza A virus infection. Intranasal (i.n.) 
influenza virus administration results in a highly localized pulmonary infection because of the 
dependence of viral replication on a trypsin-like enzyme that is largely restricted to respiratory 
epithelial cells (Steinhauer 1999). Although infected pulmonary dendritic cells are thought to 
travel to regional lymphoid tissues and spleen and drive influenza-specific T and B cell 
responses, little if any infectious virus is detected outside the lung (Eichelberger, Wang et al. 
1991; Hamilton-Easton and Eichelberger 1995; Legge and Braciale 2003). The development of 
adaptive immune responses correlates with the clearance of infectious virus from the lung, which 
is complete approximately 10 days after infection (Gerhard, Mozdzanowska et al. 1997; 
Woodland 2003). The strong influenza-specific B cell response to infection is dominated by the 
production of IgG isotypes, but there is also a substantial IgA response. Thus, the model provides 
an opportunity to compare the state of both IgG and IgA memory. Our findings provide insights 
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into the anatomically dispersed state of B cell memory established during the return to 
homeostasis following a transient, localized viral infection of the lung. 
 
Materials and METHODS 
Mice and infection 
C57BL/6J mice purchased from The Jackson Laboratory (Bar Harbor, ME) were housed 
under specific pathogen-free conditions until infection, and thereafter in BSL2 containment. 
Female mice were used in all experiments and were infected at 8-10 weeks of age. Influenza 
virus A/HKx31 (H3N2) was grown in the allantoic cavity of embryonated hen’s eggs. Mice were 
anesthetized with Avertin (2,2,2-tribromoethanol) given intraperitoneally, and then infected i.n. 
with 10
6.8
 50% egg infectious doses of influenza virus (30 l in Dulbecco’s PBS). Animal 
procedures were approved by the Animal Care and Use Committee of the University of 
Tennessee. 
 
 Tissue sampling and treatment 
Tissues collected from exsanguinated mice were processed to generate single-cell 
suspensions in IMDM (Invitrogen, Carlsbad, CA) containing L-glutamine (2 mM), sodium 
pyruvate (1 mM), penicillin (100 IU/ml), streptomycin (100 g/ml), gentamicin (10 g/ml), and 
5 x 10
-5
 M -mercaptoethanol (designated B cell medium, BCM), and supplemented with 10% 
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FBS. Lymph nodes (CLN, MedLN, ILN, and MesLN) and spleen were disrupted between the 
frosted ends of microscope slides. BM cell suspensions were obtained by flushing the femurs and 
tibiae. Red blood cells were removed from the spleen and BM preparations by ammonium 
chloride lysis. Cell populations from the o-NALT and d-NALT were collected as previously 
described (Asanuma, Thompson et al. 1997). Lungs were finely minced and incubated for 1 h at 
37°C in BCM containing 10% FBS and 4 mg/ml collagenase type II (Worthington, Lakewood, 
NJ). Cells pelleted from the lung digest were resuspended in 40% isotonic Percoll and layered 
over 75% isotonic Percoll. After centrifugation at 600g for 20 min at 25°C, cells at the interface 
were collected and washed. PP were dissected from the small intestine and washed, and cells 
were released by digestion with 2 mg/ml collagenase type I (Worthington) for 30 min at 37°C. 
Cells from heparinized blood were collected over Lympholyte-Mammal (Cedarlane, Burlington, 
NC) according to the manufacturer’s instructions. Spleens were processed individually; 
otherwise tissues were pooled from 2-5 mice to generate sufficient cells for analysis. Cell 
populations were characterized by flow cytometry using FITC-conjugated mAb to CD3  (145-
2C11) and PE-conjugated mAb CD19 (1D3; BD Biosciences) as staining reagents. 
 
Cell enrichment 
CD19
+
 B cells were enriched (purity >95%) from single cell suspensions by MACS using 
murine CD19 MicroBeads and LS columns according to the manufacturer’s instructions 
(Miltenyi Biotec). 
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ELISPOT assay 
Influenza-specific ASCs were enumerated by ELISPOT assay as previously described (Li, 
Vanitha et al. 2006). Plate-bound secreted Abs were detected using alkaline phosphatase-
conjugated goat anti-mouse Abs with specificity for IgG or IgA (Southern Biotechnology, 
Birmingham, AL). 
Memory B cell assay 
Influenza-specific BMem frequencies were determined by a previously described LDA 
based on in vitro stimulation of BMem to differentiate into ASCs (Li, Vanitha et al. 2006). Briefly, 
two-fold dilutions of cells were incubated in 96-well tissue culture plates (routinely 12 wells per 
dilution), together with 10
6
 irradiated (3000 rad) syngeneic naïve spleen cell feeders plus -
propiolactone-inactivated HKx31 (Charles River, Wilmington, MA). After incubation, cells in 
each well were transferred to ELISPOT plates for the enumeration of influenza-specific IgG or 
IgA ASCs. Pre-existing virus-specific ASC numbers at the time of sampling were determined by 
direct ex vivo ELISPOT assay. After in vitro BMem activation and ELISPOT analysis, individual 
wells were scored positive for virus-specific BMem if progeny ASC numbers were greater than 
twice the mean pre-existing ASC. The approach was modified for tissues that had high numbers 
of virus-specific ASCs at the time of sampling. For analysis of BM and d-NALT, wells were 
scored positive for BMem relative to unstimulated cultures (without inactivated-HKx31). Lung 
cell suspensions prepared 3 wk or more after infection were enriched for CD19
+
 cells to reduce 
ASC numbers before in vitro stimulation, and were compared to unstimulated cultures for 
identification of positive wells. The virus-specific BMem frequency was calculated from the 
58 
 
number of negative wells per cell dilution by extrapolation to the dilution that gave 37% negative 
wells (Topham and Doherty 1998). Linearity between the proportion of negative cultures and the 
input cell dose indicated direct measurement of BMem. Virus-specific IgG and IgA BMem were 
defined as cells that generated IgG and IgA ASCs, respectively, after in vitro stimulation 
(Okumura, Julius et al. 1976; Coffman and Cohn 1977). No influenza-specific IgG or IgA ASCs 
were detected after in vitro stimulation of spleen, lung, or PP lymphocytes from naïve mice or 
from mice infected i.n 8 wk previously with an unrelated virus (murine gammaherpesvirus 68). 
IgG and IgA BMem frequencies (per CD19
+
 cells) in the lung were similar regardless of whether 
total or CD19-enriched immune cell populations were analyzed, indicating that results were 
independent of tissue-specific non-B cell factors (Mora, Iwata et al. 2006). This was supported 
by a BMem analysis of CD19-enriched immune spleen cells stimulated in the presence of CD19-
depleted immune PP cells, or CD19-enriched immune PP cells stimulated in the presence of 
CD19-depleted immune spleen cells (data not shown).   
 
Statistical analysis 
Mean values were analyzed using one-way ANOVA and the Tukey post test for multiple 
comparisons.  The nonparametric Kruskal-Wallis test and Dunn’s post test were used as required 
to accommodate values below the limit of assay sensitivity. Tests were performed using 
GraphPad software (SanDiego, CA). Values of P < 0.05 were considered statistically significant. 
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RESULTS 
The primary influenza-specific ASC response to i.n. administered virus has been well-
characterized. Initially, responses develop in the organized nasal-associated lymphoid tissues (o-
NALT), which samples antigens in the upper respiratory tract, and in the cervical (CLN) and 
mediastinal (MedLN) lymph nodes, which drain the upper and lower respiratory tract, 
respectively(Liang, Hyland et al. 2001; Sangster, Riberdy et al. 2003). A delayed response 
develops in the spleen, presumably reflecting the transit time of antigen-laden dendritic cells 
migrating from the lung. Responses in these sites wane rapidly after the elimination of infectious 
virus. The response kinetics are notably different in the BM and in the submucosa of the upper 
and lower respiratory tract, where long-maintained populations of influenza-specific ASCs are 
established (Jones and Ada 1986; Hyland, Sangster et al. 1994; Liang, Hyland et al. 2001). To 
expand our understanding of B cell memory generated by primary influenza pneumonia, we 
determined the frequencies of virus-specific ASCs and BMem in a broad range of anatomical 
locations 8-12 weeks after infection. At this time, a fully dispersed and stabilized state of B cell 
memory would be expected (Slifka, Antia et al. 1998). 
 
Tissue distribution of influenza-specific IgG BMem 
Influenza-specific IgG BMem were present in all of the organized lymphoid tissues 
examined (Fig. 1A). BMem frequencies expressed as a proportion of total cells were significantly 
higher in the o-NALT, MedLN, and Peyer’s patches (PP) than in multiple other sites (Fig. 1A, 
legend). Interestingly, IgG BMem preferentially localized in the PP, even though influenza-
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specific ASCs were not generated at this site during the primary response to infection (data not 
shown). Notably, a relatively high BMem frequency was also present in the lung, a site of plasma 
cell concentration (Fig. 1B). The BM contained a substantial plasma cell population, but BMem 
were infrequent (<1 in 10
5
) and may have been contaminating cells in the vasculature. BMem were 
consistently present in the blood, indicating maintenance of BMem circulation long after viral 
clearance. 
There was a considerable range in the proportions of CD19
+
 B cells in the different 
anatomical sites examined, with high percentages in the o-NALT and PP and low percentages in 
the diffuse(d)-NALT and lung (Fig 1C). Enrichment and depletion experiments established that 
the CD19
+
 population contained all of the influenza-specific BMem detected in our analysis (data 
not shown). Therefore, to standardize site-to-site comparisons, influenza-specific IgG BMem 
frequencies were calculated as a proportion of CD19
+
 cells (Fig. 1D). This analysis clearly 
established anatomical differences in IgG BMem localization (P < 0.0001) and identified the 
MedLN, lung, and d-NALT as sites of preferential concentration. The proportion of IgG BMem in 
the CD19
+
 cell population was significantly higher in the MedLN than in all other sites except 
the lung and d-NALT, and was significantly higher in the lung and d-NALT compared with the 
spleen, inguinal lymph node (ILN), and blood (Fig. 1D, legend). The prominence of the o-NALT 
and PP as sites of BMem localization (Fig. 1A) was less marked after standardizing the expression 
of BMem frequencies. With this adjustment, frequencies in the o-NALT and PP were still 
consistently higher than in the spleen and some lymph nodes, but differences were not 
statistically significant. BMem frequencies did not correlate with participation of the tissue in the 
immune response to influenza, as evidenced by significantly higher frequencies in the MedLN 
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compared with the CLN (both responding sites), and similar frequencies in the CLN and non-
responding sites such as the PP and mesenteric lymph node (MesLN). The overall impression is 
one of widespread IgG BMem dispersion modulated by local tissue factors. 
The total number of IgG BMem in each anatomical location was calculated from the 
frequency and cell yield (Fig. 1E). Because of its cellularity, the spleen was by far the major 
repository with approximately 5,000 IgG BMem, representing close to two-thirds of the total IgG 
BMem measured in the analysis. 
 
Tissue distribution of influenza-specific IgA BMem 
Influenza-specific IgA BMem frequencies differed depending on anatomical location (P = 
0.0004) (Fig. 1F). Measurable IgA BMem frequencies were present on the majority of samplings 
in the o-NALT, MedLN, lung, and blood. In all other locations examined, frequencies were 
always below the level of sensitivity of the assay (frequency <1/10
5
 cells). IgA BMem frequencies 
in the o-NALT, MedLN, and lung were approximately one-tenth of the IgG BMem frequencies, 
perhaps reflecting the overall IgA:IgG composition of the primary response to infection (Fig. 2A). 
The presence of IgA BMem in the blood suggests continuous re-circulation, as was the case for 
IgG BMem. 
 
Kinetics of influenza-specific AFC and BMem generation and dispersion 
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To gain insights into the establishment of the dispersed state of B cell memory, we 
determined influenza-specific ASC and BMem frequencies in selected sites at intervals after 
infection (Fig. 2). A vigorous IgG ASC response accompanied by BMem production developed 
first in the MedLN and later in the spleen (Fig. 2A). In contrast to the peak and decline in IgG 
ASC frequencies in the MedLN and spleen, the pattern for IgG BMem was the quick 
establishment and maintenance of the frequencies that were characteristic of these tissues in the 
long-term (Fig. 2B). As early as day 7 after infection, the presence of circulating IgG BMem 
indicated that BMem dispersion from sites of generation had commenced. Notably, IgG BMem were 
detected in the lung as early as day 7 (<1/10
5
 total cells) and had increased substantially in 
numbers by day 9, raising the possibility of a functional significance of these cells during the 
acute response. A limited analysis of IgA BMem on days 9 and 14 demonstrated circulating cells 
and relatively high frequencies in the lung, emphasizing the lung as a site of rapid and 
preferential BMem localization (Fig. 2C). ASC frequencies in the lung progressively increased 
from 1-3 wk after infection and then plateaued, a kinetic pattern consistent with the immigration 
of ASCs (and presumably also BMem) from other sites, rather than local synthesis. Although IgA 
ASCs were consistently present in the blood from 1-3 wk after infection (5-10 IgA ASC/10
5
 
cells), circulating IgG ASCs were never detected, perhaps reflecting an influence of isotype 
expression on the differentiation rate of activated B cells. IgG BMem were detected earlier and 
established higher frequencies in the PP compared with the ILN, even though immune responses 
to influenza do not occur in either site. The general pattern was for IgG BMem frequencies in all 
tissues to increase and stabilize, with no evidence of contraction of the BMem pool during the 
period of analysis. 
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DISCUSSION 
The state of B cell memory generated by influenza infection of the respiratory tract 
provides profound and long-lasting resistance to reinfection with the homologous virus, as well 
as varying levels of protection against non-homologous but serologically related strains. The 
protection provided by pre-existing virus-specific Abs produced by ASCs in the upper and lower 
respiratory tract and in the BM is well-recognized. However, much less attention has been given 
to the virus-specific BMem pool, even though this is likely to be of considerable importance in 
conferring long-term protection, especially if pre-existing Ab levels begin to fall. The present 
analysis focuses on the virus-specific BMem population generated by primary influenza infection. 
Our findings are consistent with the concept of widespread BMem dispersion to secondary 
lymphoid tissues throughout the body. However, what also emerge are significant tissue-specific 
influences on BMem localization. After adjusting for the proportion of CD19
+
 cells, the MedLN, 
d-NALT, and lung stood out as sites of preferential IgG BMem localization. The high BMem 
frequency in the MedLN is not simply a consequence of a vigorous B cell response and BMem 
formation in this site, since the CLN also responds strongly to infection. Indeed, multiple site-to-
site comparisons indicate that participation in the response to infection is not a determinant of the 
IgG BMem frequency that is established. IgG BMem frequencies in the o-NALT and PP, although 
significantly lower than in the MedLN, were still consistently higher than in the spleen and some 
lymph nodes, suggesting additional complexity in the regulation of BMem localization. The set of 
expressed homing molecules that direct BMem migration is not well-established and may vary 
within the BMem population (Roy, Kim et al. 2002). Since naïve and BMem traffic through many of 
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the same lymphoid tissues, there is likely to be considerable overlap in the homing molecules 
that regulate the process (Rodrigo Mora and Von Andrian 2006). However, even subtle 
differences between naïve and memory B cells in the expression levels of homing molecules may 
be sufficient to bias BMem localization. For example, up-regulation of 4 7 on BMem (Roy, Kim 
et al. 2002) may favor entry into the PP, o-NALT, and mucosa-associated lymph nodes, where 
high endothelial venules (HEV) display relatively high levels of MadCAM-1, the 4 7 ligand 
(Csencsits, Jutila et al. 1999). Our findings may also reflect tissue differences in the rate of 
egress of lymphocytes. A key component of this process is receptor-mediated cell migration 
along an increasing sphingosine-1-phosphate (S1P) concentration gradient between the lymphoid 
tissue interior and adjacent blood or lymph (Cyster 2005). Inflammatory mediators released early 
in immune responses stimulate local overproduction of S1P in lymphoid tissues, leading to 
disruption of the S1P concentration gradient or down-regulation of cell receptors for S1P. The 
result is a transient block in lymphocyte egress from lymphoid tissues. Thus, high BMem 
frequencies in constitutively active lymphoid tissues like the PP and o-NALT may be a 
consequence of both preferential entry and delayed egress. 
Importantly, our studies demonstrate that a relatively high frequency of virus-specific 
IgG BMem is established and maintained in the lung following influenza infection. This finding 
emphasizes the complexity of the lung as a site for the localization of the cellular elements of 
adaptive immunity. Previous studies have established that virus-specific ASCs and memory 
CD4
+
 and CD8
+
 T cells persist in the lung long after influenza and other viruses that target the 
respiratory tract have been cleared (Jones and Ada 1986; Hogan, Usherwood et al. 2001; Hogan, 
Zhong et al. 2001; Ostler, Hussell et al. 2001). The kinetics of BMem (and ASC) movement into 
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the lung resembled that previously reported for virus-specific CD4
+
 and CD8
+
 T cells (Cauley, 
Cookenham et al. 2002; Roman, Miller et al. 2002; Lawrence, Ream et al. 2005). There is little 
information on molecules specifically expressed by BMem that direct entry into the lung, but at 
least initially the process is likely to resemble that for activated lymphocytes in general as they 
exit the vasculature in response to local inflammation-associated changes (Kim 2004; Luster, 
Alon et al. 2005). Up-regulation of 4 1 on BMem may be expected, since the 4 1/VCAM-1 
adhesion pathway is a key element in lymphocyte trafficking into the inflamed lung (Feng, 
Britton et al. 2000). The microanatomical location of BMem in the lung has not been identified, 
but they may come to reside primarily in the relatively organized regions of lymphoid tissue that 
form in lung within 10 days of infection (Moyron-Quiroz, Rangel-Moreno et al. 2004). This 
lymphoid tissue, collectively referred to as induced bronchus-associated lymphoid tissue (BALT), 
includes areas that resemble secondary lymphoid tissue with distinct B and T cell zones and 
HEV. Lymphocyte homing to BALT, as well as to PP and peripheral lymph nodes, is highly 
dependent on L-selectin and LFA-1 expression (Xu, Wagner et al. 2003). However, the BALT 
homing pathway may rely particularly on 4 1/VCAM-1 interactions, since VCAM-1 is 
expressed at much higher levels on BALT HEV than on HEV in other secondary lymphoid 
tissues (Xu, Wagner et al. 2003). T cell studies indicate that lung lymphocytes are part of a re-
circulating pool (Moyron-Quiroz, Rangel-Moreno et al. 2006), moving via lymphatics through 
draining lymph nodes to eventually reach the venous blood. A preferential lymphocyte 
trafficking circuit from lung → draining lymph nodes → blood → lung has been proposed 
(Zammit, Turner et al. 2006), and may underlay the high BMem frequencies that we consistently 
observed in the MedLN. The IgG BMem frequency (as a proportion of CD19
+
 cells) was also 
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relatively high in the d-NALT sample, which consisted of cells isolated from the thin tissue 
lining the nasal cavity (o-NALT excluded). This result reflects the presence of a small number of 
BMem in a tissue that contained few lymphocytes. 
Influenza-specific IgG BMem frequencies in the BM were always below the level of 
sensitivity of the assay (<1/10
5
 cells), in contrast to the concentration of LLPCs in this site. Our 
findings are consistent with other studies that reported the scarcity of BMem in the BM 
(Bachmann, Kundig et al. 1994; Slifka, Antia et al. 1998). Interestingly, this contrasts with the 
role of the BM as a significant reservoir of memory T cells (Marshall, Turner et al. 2001; Di 
Rosa and Pabst 2005). Although distinct trafficking characteristics may contribute to the 
difference between memory T and B cell frequencies in the BM (Mazo, Honczarenko et al. 
2005), another factor may be BMem differentiation in the BM microenvironment to replenish the 
LLPC population. 
Only the o-NALT, MedLN, lung, and blood had measurable influenza-specific IgA BMem 
frequencies when analyzed 8 wk or more after infection. This finding may simply reflect a 
consistent ratio of IgG:IgA BMem (approximately 10:1) in all of the solid tissues sampled, since 
this could result in IgA BMem frequencies below the level of assay sensitivity in all sites except 
the o-NALT, MedLN, and lung. Alternatively, our data can be taken to reflect preferential IgA 
BMem trafficking to the respiratory tract and associated lymphoid tissues. It is well established 
that the expression of different sets of adhesion molecules and homing receptors by IgG- and 
IgA-producing ASCs results in preferential trafficking to the BM and mucosal sites, respectively 
(Cyster 2003). There is evidence for further compartmentalization of IgA ASC trafficking, with 
preferential migration to either the small intestine or to other mucosal sites like the lung 
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(McDermott and Bienenstock 1979). Further studies are required to firmly establish whether an 
analogous situation applies to IgA BMem. Our analysis demonstrated a rapid increase in IgA BMem 
frequency in the lung during the acute response, with maintenance of a lower frequency in the 
long-term. In contrast, IgA BMem frequencies in the MedLN (presumably a key site of IgA BMem 
formation) stabilized at higher frequencies after clearance of the virus. This may reflect the 
lymphocyte trafficking pathway from lung to draining lymph nodes discussed above. 
In our analysis of the MedLN and spleen, long-term BMem frequencies (per total cells) 
were comparable to previous limiting dilution assay (LDA) determinations of memory CD4
+
 and 
CD8
+
 T cell frequencies (Tripp, Sarawar et al. 1995; Topham, Tripp et al. 1996), although more 
recent studies (for example, using tetramers) indicate that the CD8
+
 T cell frequencies may be 
somewhat higher (Flynn, Belz et al. 1998; Hogan, Usherwood et al. 2001; Hogan, Zhong et al. 
2001). A more dramatic difference exists in the lung; at least when comparing memory B and 
CD8
+
 T cell frequencies (and numbers). During the memory phase after a primary infection, 
influenza-specific CD8
+
 T cell numbers in the lung may exceed our estimate of BMem numbers by 
up to 100-fold (Hogan, Usherwood et al. 2001; Lawrence, Ream et al. 2005). This difference 
may be much less marked for memory CD4
+
 T cells, which decrease in frequency in the lung 
much more rapidly than do CD8
+
 T cells after viral clearance (Cauley, Cookenham et al. 2002). 
A stable population of approximately 30,000 influenza-specific ASCs was maintained in the lung 
following infection. These cells, which can be considered the effector form of BMem, are 
numerically more comparable to the memory CD8
+
 T cell population in the lung. It is not known 
whether our LDA strategy underestimates influenza-specific BMem frequencies, as was shown to 
be the case for LDA analysis of CD8
+
 T cell frequencies prior to the introduction of tetramers. 
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However, at present, our approach may be the best option for enumerating a BMem population 
representing specificities for multiple, often poorly defined epitopes on different molecules. 
In summary, the current report provides the most comprehensive picture currently 
available of the dispersed virus-specific BMem pool generated by primary influenza infection. 
Perhaps primarily, our findings focus attention on the lung as a complex repository of B and T 
cell memory that may contribute substantially to resistance to respiratory infections. The concept 
of effector lymphoid tissue (ELT) has been introduced to describe the stable accumulations of 
functionally significant memory T cells that are established in non-lymphoid tissues as a 
consequence of infection (van Panhuys, Perret et al. 2005). Our studies demonstrate that BMem 
(as well as ASCs) should be recognized as components of the ELT that develops in the lung 
following influenza infection. Future studies are required to relate BMem numbers, location, and 
isotype expression to protective immunity and may have important implications for vaccine 
development. 
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Figure 1. Quantitative analysis of anatomically dispersed influenza-specific BMem and ASCs. 
Mice were sampled 8-12 wk after i.n. influenza infection. Abbreviations: o-NLT, organized 
nasal-associated lymphoid tissue; CLN, cervical lymph node; Med, mediastinal lymph node; Spl, 
spleen; ILN, inguinal lymph node; PP, Peyer’s patches; Mes, mesenteric lymph node; BM, bone 
marrow; d-NLT, diffuse nasal-associated lymphoid tissue. (A) IgG BMem frequencies expressed 
as a proportion of total cells. BMem frequencies (A, F) were determined by LDA based on in vitro 
stimulation of BMem to generate ASCs. Formation of IgG and IgA ASCs were taken to reflect 
precursor IgG and IgA BMem respectively. P < 0.0001 for frequency differences among 
anatomical locations. 
a
o-NLT vs ILN, d-NLT, and blood (P < 0.001), and vs CLN, spleen, and 
Mes (P < 0.01). 
b
Med vs CLN, Spl, ILN, Mes, d-NLT, lung, and blood (P < 0.001). 
c
PP vs ILN, 
d-NLT, and blood (P < 0.05). Data are mean + s.e.m. (n = 4-6 for PP, Mes, BM, d-NLT, and 
blood; otherwise n = 8-12). (B) IgG and IgA ASCs were enumerated by direct ex vivo ELISPOT 
assay and are expressed as a proportion of total cells. Data are mean + s.e.m. (n = 5-12). (C) 
Percentages of B cells (CD19
+
) and T cells (CD3
+
) were determined by flow cytometry. Data are 
mean + s.e.m. (n = 5-12). (D) IgG BMem frequencies shown in A expressed as a proportion of 
CD19
+
 cells. Data are mean + s.e.m. P < 0.0001 for frequency differences among anatomical 
locations. 
a
Med vs CLN, Spl, ILN, and blood (P < 0.001), vs o-NLT and Mes (P < 0.01), and vs 
PP (P < 0.05). 
b
d-NLT vs ILN and blood (P < 0.01), and vs Spl (P < 0.05). 
c
Lung vs vs ILN and 
blood (P < 0.01), and vs Spl (P < 0.05). (E) Total IgG BMem were calculated from the frequency 
(shown in A) and cell yield. Data are mean + s.e.m. (F) IgA BMem frequencies expressed as a 
proportion of CD19
+
 cells. Only tissues that had measurable IgA BMem frequencies on at least 
one occasion are shown. The median of each group is indicated by a line. Frequencies were 
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below the level of assay sensitivity in the following tissues (n = 3-5): CLN, Spl, ILN, PP, Mes, 
and BM. P = 0.0004 for frequency differences among all anatomical locations analyzed. IgA 
BMem frequencies were not significantly different in pairwise comparisons of anatomical 
locations. 
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 Figure 2. Kinetic analysis of influenza-specific ASC and BMem generation and dispersion. Mice 
were sampled at intervals after i.n. influenza infection. Data for days 56-84 from the analysis 
shown in Fig. 1 are included for comparison. Abbreviations: MedLN, mediastinal lymph node; 
ILN, inguinal lymph node; PP, Peyer’s patches. (A) IgG and IgA ASC frequencies in the MedLN, 
spleen, and lung were enumerated by direct ex vivo ELISPOT assay and are expressed as a 
proportion of total cells. Data are mean + s.e.m. (n = 3-7 for days 7-28). (B) IgG BMem 
frequencies in the MedLN, spleen, lung, ILN, PP, and blood expressed as a proportion of CD19
+
 
cells. Frequencies were determined by LDA based on in vitro stimulation of BMem to generate 
ASCs. Formation of IgG ASCs was taken to reflect precursor IgG BMem. Data are mean + s.e.m. 
(n = 3 for days 7-28). *The IgG BMem frequency in the responding MedLN on day 7 was >1/10
5
 
cells, but could not be accurately measured by LDA. (C) IgA BMem frequencies in the MedLN, 
spleen, lung, ILN, PP, and blood expressed as a proportion of CD19
+
 cells. Frequencies were 
determined as for B, with formation of IgA ASCs taken to reflect precursor IgA BMem. Data are 
mean + range (n = 2).           
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Chapter 4 
Quantitative analysis of influenza virus-specific B cell 
memory generated by different routes of inactivated 
virus vaccination 
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 Abstract 
The humoral response to inactivated viral vaccines generates a state of B cell memory in 
the form of Ab-secreting cells (ASCs) and memory B cells (BMem) that determines protective 
efficacy. Although the activation of BMem by recall Ag contributes substantially to protection, the 
population characteristics of BMem generated by vaccination has received little attention. Here, 
we consider both ASC and BMem populations in a quantitative analysis of virus-specific B cell 
memory generated by intramuscular or intranasal vaccination of mice with inactivated influenza 
virus. The memory phase after both forms of vaccination was characterized by localization of 
ASCs in the bone marrow and dispersion of BMem to organized lymphoid tissues. Other features 
of B cell memory reflected the form of vaccination: the stronger IgG response to intramuscular 
vaccination correlated with larger numbers of IgG ASCs in the bone marrow and IgG BMem; IgA 
production was only prominent in the response to intranasal vaccination and was associated with 
IgA ASC localization in the lung and IgA BMem formation. Nevertheless, the BMem pools 
generated by both forms of vaccination were comparably effective in responding to viral 
challenge. Notably, few IgG ASCs or BMem localized in the lung after intramuscular vaccination, 
a marked contrast with the preferential localization of ASCs and BMem in the lung following 
influenza pneumonia. Our analysis links the route of Ag administration to characteristics of B 
cell memory that may relate to protective immunity, and emphasizes the potentially suboptimal 
state of B cell memory in the lung after intramuscular vaccination.  
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Introduction 
Characteristics of the B cell response, and particularly the nature of long-term B cell 
memory, are key determinants of the protective capacity of many vaccines (Subbarao and Joseph 
2007). Ab-secreting cells (ASCs)
3
 generated during B cell responses and persisting into the 
memory phase provide one component of B cell memory (McHeyzer-Williams and McHeyzer-
Williams 2005). Long-lived ASCs are primarily recognized as a bone marrow (BM)-resident 
population that maintains circulating Ab levels (Hyland, Sangster et al. 1994; Slifka, Antia et al. 
1998). ASC populations may also be established and maintained at mucosal surfaces, typically 
following mucosal immunization (Jones and Ada 1986; Liang, Hyland et al. 2001). A second 
cellular component of B cell memory is formed by memory B cells (BMem) which are generated 
in parallel with ASCs during B cell responses (Anderson, Tomayko et al. 2006). BMem are long-
lived, non-ASCs that, upon activation, divide and differentiate into ASCs and mediate the rapid, 
vigorous, and high affinity secondary Ab response (Ahmed and Gray 1996). The contribution of 
the BMem response to protection is particularly important when pre-existing ASC numbers (and 
thus Ab levels) begin to wane. 
 As a result of recent studies, a more complete picture of the BMem pool generated by viral 
infection is emerging. It is now well-established that BMem generated during the acute response 
circulate and disperse to secondary lymphoid tissues throughout the body (Bachmann, Kundig et 
al. 1994; Vanitha, Joo et al. 2007; Joo, He et al. 2008). In addition, some non-lymphoid organs 
that are a target of infection may become significant repositories of BMem, perhaps reflecting de 
novo lymphoid tissue formation in these locations (Carragher, Rangel-Moreno et al. 2008). An 
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analysis of B cell memory induced by influenza infection identified the lung as a site where BMem 
(as well as ASCs) preferentially localize (Joo, He et al. 2008). 
In contrast to the situation following infection, little information is available on the nature 
of BMem populations generated by vaccination. These cells are likely to be especially important 
when the protective efficacy of a vaccine is largely determined by its ability to elicit a humoral 
response. Such vaccines include the most widely used form of influenza vaccine, an inactivated 
split virus preparation that is administered i.m (Gerdil 2003). Generally, influenza-specific 
circulating Ab levels induced by this vaccine have declined by 6 mo after immunization (Powers, 
Smith et al. 1995; Kunzel, Glathe et al. 1996), but a longer-lasting BMem pool remains to respond 
to recall Ag and enhance resistance to infection (Wrammert, Smith et al. 2008). Here we report a 
comprehensive quantitative analysis of the state of virus-specific B cell memory generated by 
vaccination with inactivated influenza virus. Our analysis considers the BMem and ASC 
populations resulting from i.m. or intranasal (i.n.) Ag administration. We show that parameters 
of B cell memory that may relate to the level of protective immunity are influenced by the route 
of immunization. In particular, our analysis emphasizes the marked difference between B cell 
memory in the lung generated by i.m. vaccination and the situation following influenza 
pneumonia. 
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Materials and methods 
Mice and immunizations 
C57BL/6J mice purchased from The Jackson Laboratory (Bar Harbor, ME) were housed 
under specific pathogen-free conditions. Female mice were used in all experiments and were 
immunized at 8-12 weeks of age. The Animal Care and Use Committee of the University of 
Tennessee approved all animal procedures. 
Preparations of sucrose gradient-purified influenza virus A/HKx31 (H3N2) inactivated by 
treatment with formaldehyde or -propiolactone were purchased from Charles River 
(Wilmington, MA). Results were not affected by the method of inactivation. A stock of 
infectious influenza virus HKx31 was grown and titrated in the allantoic cavity of embryonated 
hen’s eggs. Mice were anesthetized with Avertin (2,2,2-tribromoethanol) given i.p. before all 
immunizations. For i.m. vaccination, a total dose of 20 g of inactivated virus was given in two 
injections, each of 10 g (50 l in PBS), into the tibialis anterior muscle of each leg. A plastic 
sleeve over the needle controlled the depth of injection. The dose of inactivated virus for i.n. 
vaccination was 30 g (30 l in PBS). Vaccinated mice were challenged i.n. with 10
6.8 
50% egg 
infectious doses of influenza virus (30 l in PBS). 
  
Tissue sampling and treatment 
Anesthetized mice were exsanguinated via the retro-orbital plexus before tissue sampling. 
Tissues were processed to generate single-cell suspensions in IMDM (Invitrogen, Carlsbad, CA) 
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containing L-glutamine (2 mM), sodium pyruvate (1 mM), penicillin (100 IU/ml), streptomycin 
(100 g/ml), gentamicin (10 g/ml), and 5 x 10
-5
 M -mercaptoethanol (designated B cell 
medium), and supplemented with 10% FBS. Lymph nodes and spleen were collected and gently 
disrupted between the frosted ends of microscope slides. BM cell suspensions were obtained by 
flushing the femurs and tibiae. RBCs were removed from the spleen and BM preparations by 
ammonium chloride lysis. The organized nasal-associated lymphoid tissue was collected 
attached to the palate (Asanuma, Thompson et al. 1997) and cells were released by teasing. 
Lungs were finely minced and incubated for 1 h at 37°C in B cell medium containing 10% FBS 
and 4 mg/ml collagenase type II (Worthington, Lakewood, NJ). Cells pelleted from the lung 
digest were resuspended in 40% isotonic Percoll and layered over 75% isotonic Percoll. After 
centrifugation at 600g for 20 min at 25°C, cells at the interface were collected and washed. PP 
were dissected from the small intestine and washed, and cells were released by digestion with 2 
mg/ml collagenase type I (Worthington) for 30 min at 37°C. Blood was collected into heparin 
sodium (1,000 USP Units/ml, Abraxis, Schaumburg, IL), diluted in an equal volume of HBSS 
containing 0.1% BSA, layered over Lympholyte-Mammal (Cedarlane, Burlington, NC) and 
centrifuged at 800g for 20 min at 25°C. Cells at the interface were then collected and washed.  
Lungs to be titrated for infectious virus were homogenized in 1 ml HBSS containing 0.1% 
BSA. Homogenates were clarified by centrifugation, and supernatants were stored at -80°C. 
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Virus titration 
Viral titers in lung homogenates were determined by 50% tissue culture infective dose 
assay using Madin Darby canine kidney cells grown in MEM containing L-glutamine (2 mM),  
penicillin (100 IU/ml), streptomycin (100 g/ml), and 5% FBS. Confluent cell monolayers in 96-
well tissue culture plates were washed once with serum-free MEM immediately before the 
addition of viral inocula. Serial 10-fold dilutions of lung homogenates were prepared in MEM 
containing 0.3% BSA and 1 g/ml L-(toslyamido 2-phenyl) ethyl chloromethyl ketone-treated 
trypsin (Worthington), and 0.2 ml volumes were added to the appropriate wells. After 2 days 
incubation at 37°C with 5% CO2, wells positive for virus growth were identified by the presence 
of hemagglutinating activity. 
 
ELISPOT assay 
Influenza-specific ASCs were enumerated by ELISPOT assay as previously described (Li, 
Vanitha et al. 2006). Briefly, plates were coated with purified influenza HKx31 (Charles River) 
and single cell suspensions were plated and incubated. Alkaline phosphatase-conjugated goat 
anti-mouse Abs with specificity for Ig isotypes or IgG (Southern Biotechnology, Birmingham, 
AL) were used in combination with the substrate 5-bromo-4-chloro-3-indolyl phosphate (Sigma, 
St. Louis, MO) to generate spots. 
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ELISA 
Influenza-specific Ab levels in sera were determined by ELISA (Sangster, Topham et al. 
2000) using plates coated with purified, detergent-disrupted influenza HKx31 (0.5 g/well). 
Briefly, serial 3-fold serum dilutions were added to the plates, and bound Ab was detected with 
ALP-conjugated goat anti-mouse IgG (Southern Biotechnology) and p-nitrophenyl phosphate 
substrate. Ab concentrations in arbitrary units were calculated from standard curves constructed 
using goat anti-mouse IgG capture Ab and a purified mouse Ig standard (Southern 
Biotechnology).  
  
Memory B cell assay 
Influenza-specific BMem frequencies were determined by a previously described limiting 
dilution assay based on in vitro stimulation of BMem to differentiate into ASCs (Li, Vanitha et al. 
2006). Briefly, two-fold dilutions of cells from immune mice were incubated in 96-well tissue 
culture plates (routinely 12 wells per dilution starting with 10
5
 cells per well), together with 10
6
 
irradiated (3000 rad) syngeneic naïve spleen cell feeders plus -propiolactone-inactivated 
HKx31. Plates were incubated for 4 days at 37°C in a humidified atmosphere containing 5% CO2. 
After incubation, cells in each well were washed thoroughly and transferred to ELISPOT plates 
for the enumeration of influenza-specific IgG or IgA ASCs. Pre-existing virus-specific ASC 
numbers in immune cell populations at the time of sampling were determined by direct ex vivo 
ELISPOT assay. After in vitro BMem activation and ELISPOT analysis, individual wells were 
scored positive for virus-specific BMem if progeny ASC numbers were greater than twice the 
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mean pre-existing ASC. The virus-specific BMem frequency was calculated from the number of 
negative wells per cell dilution by extrapolation to the dilution that gave 37% negative wells 
(Topham and Doherty 1998). BMem frequencies of less than one per 10
5
 input cells could not be 
accurately determined. Virus-specific IgG and IgA BMem were defined as cells that generated IgG 
and IgA ASCs, respectively, after in vitro stimulation (Okumura, Julius et al. 1976; Coffman and 
Cohn 1977). At the time of sampling, cell populations were characterized by flow cytometry 
using FITC-conjugated anti-CD3  (145-2C11) and PE-conjugated anti-CD19 (1D3) mAbs (BD 
Biosciences, San Diego, CA) as staining reagents. Spleens were processed individually; 
otherwise tissues were generally pooled from 2-5 mice to generate sufficient cells for analysis. 
To accomodate tissue differences in the proportion of CD19
+
 B cells, the population that 
includes the BMem (Bell and Gray 2003; Blink, Light et al. 2005; Li, Vanitha et al. 2006), BMem 
frequencies are expressed for CD19
+
 cells. 
 
Statistical analysis 
Mean BMem values were analyzed using one-way ANOVA and the Tukey post test for 
multiple comparisons.  The nonparametric Kruskal-Wallis test and Dunn’s post test were used as 
required to accommodate BMem values below the limit of assay sensitivity. Other comparisons of 
group means were performed using the nonparametric Mann-Whitney U test for unpaired 
samples. Tests were performed using GraphPad software (SanDiego, CA). Values of P < 0.05 
were considered statistically significant. 
 
84 
 
Results 
Influenza-specific Ab responses to intramuscular and intranasal administration of 
inactivated virus 
Initial experiments evaluated the magnitude and quality of the influenza-specific ASC 
response following two routes of administration of inactivated virus. The i.m. route was used to 
model human vaccination with inactivated influenza virus, and the i.n. route was included to 
determine whether mucosal Ag administration influenced parameters of B cell memory. 
Influenza-specific ASCs in different tissues were enumerated by ELISPOT assay. Responses in 
the draining lymph nodes and the spleen after i.m. vaccination were characterized by early IgM 
production, followed by increased numbers of cells producing IgG2c and, to a lesser degree, 
IgG2b (Fig 1). IgG production in responding lymphoid tissues was weaker following i.n. 
compared with i.m. vaccination (Fig 2), likely reflecting some loss of effective Ag following 
mucosal administration. However, the response to i.n. vaccination included a substantial IgA 
component (see CLN and spleen), which was essentially absent in the response to i.m. 
vaccination. 
 Responses in draining lymph nodes and spleen had substantially waned by 3 wk after 
vaccination by both routes, but ASC populations were established in the BM and maintained into 
the memory phase (Fig 3A and D). BM ASC populations reflected the isotype composition of the 
acute response, with IgG or IgA ASCs predominating after i.m. or i.n. vaccination, respectively. 
Higher IgG ASC numbers in the BM and serum IgG levels following i.m. compared with i.n. 
vaccination were consistent with a generally stronger acute IgG response (Fig 3C and F). 
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 IgA ASCs generated by i.n. vaccination localized in the lung as well as in the BM (Fig 
3D and E). In contrast, very few IgG ASCs were detected in the lung after either route of 
vaccination (Fig 3B and E), consistent with the notion of differential ASC trafficking patterns 
related to isotype expression. 
 
Influenza-specific BMem generated by intramuscular and intranasal vaccination with 
inactivated virus 
Influenza-specific BMem frequencies in a range of anatomical locations were measured by 
limiting dilution analysis 8-12 wk after vaccination, a time when fully dispersed and stable BMem 
populations would be expected. To standardize site-to-site comparisons, BMem frequencies were 
calculated as a proportion of CD19
+
 cells, the cell population that contained the influenza-
specific BMem in this analysis (Joo, He et al. 2008). IgG BMem generated by i.m. vaccination 
dispersed widely to all secondary lymphoid tissues sampled (Fig 4A). Significant variation 
among mean IgG BMem frequencies in these tissues (p < 0.02) indicated local influences on 
trafficking. Participation of the tissue in the immune response to vaccination did not correlate 
with higher BMem frequencies. IgG BMem were consistently detected in the blood, indicating a 
process of continuous recirculation. Lymphocyte populations isolated from the lung after i.m. 
vaccination occasionally contained influenza-specific IgG BMem, but frequencies were generally 
below the limit of sensitivity of the assay, a situation that contrasted with preferential 
localization of BMem in the lung after influenza pneumonia (Joo, He et al. 2008). 
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 IgG BMem frequencies were markedly lower after i.n. compared with i.m. vaccination (Fig 
4B), reflecting the relatively weaker acute IgG response. The presence of IgG BMem in all of the 
sampled sites was evident by the presence of influenza-specific IgG ASC after in vitro 
stimulation, emphasizing broad dispersion of these cells and continuous recirculation. However, 
only the o-NALT, MLN, and PP consistently had BMem frequencies above the limit of assay 
sensitivity after i.n. vaccination. Significant variation among mean IgG BMem frequencies (p < 
0.001) indicated a non-uniform pattern of dispersion to organized lymphoid tissues. IgG BMem 
were infrequent in the lung, indicating that preferential BMem localization in this tissue (Joo, He 
et al. 2008) is not simply a consequence of i.n. Ag administration. 
 A limited analysis of the CLN, MLN, o-NALT, and lung indicated a higher frequency of 
IgA BMem after i.n. compared with i.m. vaccination, consistent with the isotype composition of 
the primary response. Only cell populations (particularly o-NALT cells) from i.n. vaccinated 
mice gave rise to influenza-specific IgA ASCs during in vitro stimulation of limiting dilution 
cultures, indicating the presence of precursor IgA BMem (data not shown). However, IgA BMem 
frequencies were less than 1 in 10
5
 CD19
+
 cells and could not be accurately determined.  
 To further evaluate BMem populations generated by inactivated virus vaccination, mice 
primed by the i.m. or i.n. routes were challenged i.n. with live homologous virus. The Ag load 
following challenge may have differed in the two groups of primed mice because of differences 
in the levels of pre-existing local and systemic Abs (Fig 3). Nevertheless, the route of 
vaccination markedly influenced the isotype composition of the secondary response. The 
secondary response in the CLN of i.n. primed mice had a strong IgA component (Fig 5), 
consistent with a higher proportion of IgA BMem. There was a small IgA component in the 
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secondary response of i.m. primed mice, even though IgA BMem in these mice were not detected 
by limiting dilution analysis. Both i.m. and i.n. priming provided a high level of protection. At 
the time of sampling (day 5), infectious virus titers in the lungs of both groups of primed mice 
were not significantly different, and were more than 100-fold lower than in the lungs of 
unprimed mice (data not shown). 
    
Lung localization of B cell memory is poorly induced by intramuscular vaccination 
A recent study of virus-specific B cell memory generated by influenza pneumonia 
identified the lung as a site of preferential localization of ASCs and BMem (Joo, He et al. 2008). 
In contrast, the current analysis of the response to a single i.m. vaccination demonstrated 
systemic B cell memory, but very few ASCs or BMem in the lung (Figs 3 and 4). To test for an 
effect of response magnitude, the state of B cell memory in the lung was evaluated after priming 
and boosting with inactivated virus given i.m. Effective expansion of influenza-specific B cell 
memory by boosting was indicated by a vigorous secondary B cell response in draining lymph 
nodes and a significant increase in IgG ASC numbers in the BM and serum IgG levels (Fig 6A-
D). However, there was no significant change in the minimal numbers of ASCs or BMem present 
in the lung (Fig 6E and F). Surprisingly, IgG BMem frequencies in the spleen were not obviously 
increased by boosting, raising the possibility that BMem expansion does not parallel ASC 
formation. Overall, the impression is that factors other than response magnitude regulate 
localization of B cell memory in the lung. 
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Discussion 
The state of B cell memory in the form of ASCs and BMem is the critical determinant of 
the protective efficacy of inactivated viral vaccines. Our analysis provides a comprehensive 
quantitative picture of the state of virus-specific B cell memory generated by i.m. and i.n. 
vaccination with inactivated influenza virus. The localization and maintenance of ASC 
populations in the BM (Hyland, Sangster et al. 1994; Slifka, Antia et al. 1998) and the 
continuous circulation and broad dispersion of BMem to organized lymphoid tissues (Bachmann, 
Kundig et al. 1994; Vanitha, Joo et al. 2007; Joo, He et al. 2008) are established features of B 
cell memory that were common to both forms of vaccination. However, other features that may 
impact protective efficacy depended on the route of Ag administration. 
 The i.m. administration of inactivated virus is widely used for human influenza 
vaccination (Nichol and Treanor 2006). The levels of circulating IgG induced by this strategy 
correlate with resistance to influenza in humans (Cox, Brokstad et al. 2004), but Ab levels 
typically begin to fall after vaccination (Powers, Smith et al. 1995; Kunzel, Glathe et al. 1996). 
As this happens, BMem and the rapid recall response they mediate are likely to become 
increasingly important determinants of protection (Wrammert, Smith et al. 2008). In our analysis, 
acute IgG production was appreciably stronger following i.m. compared with i.n. vaccination, 
probably simply reflecting differences in the efficiency of Ag delivery to the immune system. 
The stronger IgG response correlated with a larger IgG ASC population in the BM, higher 
circulating IgG levels, and a quantitatively greater IgG BMem pool. Our analysis establishes that 
IgG BMem generated by i.m. vaccination would have rapid access to Ag entering the body via any 
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route, as reflected in the vigorous secondary Ab response following i.n. influenza challenge. In 
particular, localization of BMem in organized lymphoid tissues associated with the respiratory 
tract would ensure prompt activation in the event of influenza infection. Furthermore, the 
presence of BMem in the circulation suggests a mobile population that continuously traffics 
through lymphoid tissues surveying for cognate Ag. 
As would be expected in a comparison of mucosal and non-mucosal Ag administration, 
IgA production was prominent in the response to i.n. but not to i.m. vaccination (Neutra and 
Kozlowski 2006), and this was reflected in differences in the state of B cell memory. Only i.n. 
vaccination resulted in a durable IgA ASC population in the lung, thus providing a potentially 
valuable, broadly protective barrier to infection at the site of virus encounter. In addition, the 
BMem population generated by i.n. vaccination included a greater number of IgA BMem. A 
practical benefit of this is suggested by the substantial IgA component of the secondary B cell 
response to i.n. challenge of i.n. vaccinated compared with i.m. vaccinated mice (Fig. 5). Rapid 
BMem activation is undoubtedly a valuable protective response, regardless of the Ab isotype 
expression profile. However, the presence of IgA BMem may confer an additional advantage, 
since IgA ASCs generated by IgA BMem activation would rapidly localize to sites of viral 
replication in the upper respiratory tract (Liang, Hyland et al. 2001; Sangster, Riberdy et al. 
2003). Interestingly, the secondary response to i.n. challenge of i.m. vaccinated mice included an 
IgA component (Fig. 5), perhaps reflecting the activation of small numbers of IgA BMem. 
Analysis of lymphoid tissue populations after i.m. vaccination did not identify IgA BMem, but this 
may reflect numbers below the limit of assay sensitivity. It may be noteworthy that IgA ASCs 
were not completely absent from the response to i.m. vaccination. The presence of IgA ASCs in 
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the BM after i.m. vaccination (Fig. 3A) suggests a germinal center origin (Smith, Light et al. 
1997) and it is therefore likely that some IgA BMem were generated in parallel. Alternatively, IgG 
BMem may retain the potential to switch to IgA expression when activated in an IgA-inductive 
environment. 
The state of B cell memory in the lung following influenza infection is profoundly 
different from that following i.m. vaccination. Recent analysis of a mouse model of influenza 
pneumonia demonstrated preferential localization of IgG- and IgA-expressing ASCs and BMem in 
the lung (Joo, He et al. 2008). In contrast, the current analysis detected few virus-specific ASCs 
or BMem in the lung after i.m. vaccination, and the situation was unchanged after a second i.m. 
immunization to expand B cell memory (Fig. 6). Data presented in Fig. 7 emphasize the contrast 
in ASC and BMem localization after influenza infection and i.m. vaccination: infection resulted in 
approximately 10-fold higher ASC frequencies in the lung than in the BM, and approximately 3-
fold higher IgG BMem frequencies in the lung than in the spleen; i.m. vaccination resulted in 
essentially the opposite ratios with preferential localization of ASCs in the BM and BMem in the 
spleen. Apparently, ASC and BMem trafficking to the lung is modulated by local environmental 
factors associated with influenza infection. Factors associated with inflammation are likely to 
play a role, but mechanisms may differ depending on cell type and Ab isotype expression. 
The stable population of approximately 30,000 virus-specific ASCs established in a 
mouse lung after influenza infection consists of similar numbers of IgA and IgG ASCs (Joo, He 
et al. 2008). Molecular interactions that regulate ASC homing to the lung are not fully 
understood. IgA ASCs are programmed to migrate to mucosal sites by the expression of 
chemokine receptors responsive to ligands constitutively produced at mucosal locations. The 
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expression of different chemokine receptors may direct IgA ASC trafficking to specific mucosal 
compartments, such as the lung or the small intestine (Mora and von Andrian 2009). 
Interestingly, chemokine receptor expression may be influenced by the site of cell activation, 
such that IgA ASCs formed in lymph nodes draining the respiratory tract are programmed to 
home to the lung (McDermott and Bienenstock 1979). The regulation of IgG ASC trafficking is 
somewhat different (Cyster 2003). IgG ASCs express CXCR4 and generally localize in the BM 
in response to the production of CXCL12, the CXCR4 ligand. However, at least a proportion of 
IgG ASCs also express CXCR3 and are responsive to chemokines produced at sites of 
inflammation (Hauser, Debes et al. 2002). CXCL12 production may be upregulated at 
inflammatory sites (Nanki, Hayashida et al. 2000), and circulating inflammation-associated 
molecules decrease CXCL12 levels in the BM (Ueda, Yang et al. 2004). The potential for IgG 
ASCs to bind to activated endothelium and enter sites of inflammation is enhanced by expression 
of P-selectin glycoprotein ligand-1 and 4 1 (Underhill, Minges Wols et al. 2002). Overall, the 
impression is that IgA ASCs, and perhaps specifically those generated in lymph nodes draining 
the respiratory tract, are pre-programmed to home to the lung, whereas IgG ASC trafficking is 
modulated by ongoing inflammation, as would occur during influenza infection. Our 
observations are consistent with this scenario. Lung inflammation is unlikely to be a 
consequence of the i.m. (in particular) or i.n. administration of inactivated virus. Thus, IgG ASCs 
generated by i.m. vaccination localized in the BM but not in the lung, and lung localization of 
ASCs after i.n. vaccination was essentially limited to IgA ASCs. Little information is available 
on molecules expressed by BMem that direct entry into the lung. IgG BMem were readily detectable 
in diverse lymphoid tissues after i.m. vaccination but, in contrast to the situation after influenza 
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infection, few localized in the lung. Inflammation in the lung may also be a prerequisite for at 
least IgG BMem localization. A consequence of influenza infection is formation in the lung of 
regions of relatively organized lymphoid tissue referred to as inducible bronchus-associated 
lymphoid tissue (iBALT) (Moyron-Quiroz, Rangel-Moreno et al. 2004). The iBALT has 
characteristics of secondary lymphoid tissue and may provide a microenvironment for the 
concentration of BMem (and perhaps ASCs), but this has not been established. 
Our analysis of the state of B cell memory generated by i.m. vaccination emphasizes a 
number of features that provide valuable protection against influenza. It is well-recognized that 
this vaccination strategy effectively generates circulating virus-specific IgG that is likely 
maintained by BM ASCs. Ready access of circulating IgG to sites of influenza replication, 
especially in the lower respiratory tract, is likely to result from transudation, and this would be 
enhanced by local inflammation (Persson, Erjefalt et al. 1998). Importantly, our analysis 
establishes that the BMem pool generated by i.m. vaccination has characteristics that ensure a 
potent secondary B cell response to influenza infection. However, our analysis also raises the 
possibility that the state of B cell memory established in the lung after i.m. vaccination is 
suboptimal. In particular, this is suggested by a consideration of the situation following influenza 
infection. What remains to be determined is the protective advantage of lung localization of the 
cellular elements of B cell memory. Certainly, a case can be made for the value of virus-specific 
ASCs in the lung. It is well-established that IgA produced by submucosal ASCs is transcytosed 
across epithelial cells to provide a barrier to infection at the luminal surface. IgG produced by 
ASCs in the lung parenchyma may supplement this barrier, perhaps after transcytosis across 
respiratory tract epithelial cells by a process involving FcRn (Spiekermann, Finn et al. 2002). 
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The advantage of a lung-localized BMem population is less clear, although these cells are well-
positioned to respond rapidly to influenza infection. Future studies aimed at understanding the 
relationship between B cell memory in its various forms and protective immunity will be 
important for the optimization of vaccination strategies.   
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Figure 1. The acute influenza-specific ASC response to i.m. vaccination. The kinetics of virus-
specific ASC responses in the popliteal lymph node (A), inguinal lymph node (B), iliac lymph 
node (C), and spleen (D) were determined for mice vaccinated i.m. with inactivated influenza 
virus. The ELISPOT assay was used to enumerate influenza-specific ASCs in cell suspensions 
from individual mice. Results are expressed as the number of ASC/5 x 10
5
 nucleated cells. Data 
are mean + SE (n = 3-5). 
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Figure 2. The acute influenza-specific ASC response to i.n. vaccination. The kinetics of virus-
specific ASC responses in the cervical lymph node (A), mediastinal lymph node (B), and spleen 
(C) were determined for mice vaccinated i.n. with inactivated influenza virus. The ELISPOT 
assay was used to enumerate influenza-specific ASCs in cell suspensions from individual mice. 
Results are expressed as the number of ASC/5 x 10
5
 nucleated cells. Data are mean + SE (n = 3-
7). 
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Figure 3. ASC populations in BM and lung and circulating IgG levels after vaccination. 
Responses are shown after i.m. (A, B and C) and i.n. (D, E and F) vaccination with inactivated 
influenza virus. Virus-specific ASC numbers in the BM (A and D) and lung (B and E) were 
determined by ELISPOT assay and are expressed per 5 x 10
5
 nucleated cells. Serum 
concentrations of virus-specific IgG (C and F) were determined by ELISA and are expressed in 
arbitrary units. Data are mean + SE (n = 3-7). 
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Figure 4. Distribution of influenza-specific IgG BMem after vaccination. IgG BMem frequencies in 
different anatomical locations are shown 8-12 wk after i.m. (A) and i.n. (B) vaccination. PLN, 
popliteal lymph node; IliLN, iliac lymph node; IngLN, inguinal lymph node; PP, Peyer’s patches; 
oNALT, organized nasal-associated lymphoid tissues; CLN, cervical lymph node; MLN, 
mediastinal lymph node. Individual spleens were analyzed; otherwise cells were pooled from 
two or more mice. BMem frequencies were determined by limiting dilution assay based on in vitro 
stimulation of IgG BMem to generate IgG ASCs. Frequencies are expressed as a proportion of 
CD19
+
 cells to accommodate differences in the proportion of B cells in different locations. Data 
are mean + SE (n = 3-10). Mean IgG BMem frequencies varied significantly among organized 
lymphoid tissues (i.e. exclusive of lung and blood) after i.m. (p < 0.02) and i.n. (p < 0.001) 
vaccination. 
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Figure 5. The influenza-specific secondary ASC response after viral challenge of vaccinated 
mice. Mice were vaccinated i.m. or i.n. with inactivated virus, and challenged with infectious 
influenza virus given i.n. 12 wk after priming. Virus-specific ASC frequencies in the cervical (A) 
and mediastinal (B) lymph nodes of individual mice were determined by ELISPOT assay 5 d 
after challenge of vaccinated control mice. The response in naïve mice is shown for comparison. 
Results are expressed as the number of ASC/10
5
 nucleated cells. Data are mean + SE (n = 5-9). 
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Figure 6. Influenza-specific B cell memory after i.m. priming and boosting with inactivated 
virus. Primed mice were boosted with an identical i.m. vaccination after 8 wk. Virus-specific 
ASC frequencies were determined by ELISPOT assay and are expressed as a proportion of 
nucleated cells. Virus-specific IgG BMem frequencies were determined by limiting dilution 
analysis based on in vitro stimulation of BMem to generate ASCs and are expressed as a 
proportion of CD19
+
 cells. Lungs were pooled from 2-3 mice for BMem analysis; otherwise data 
points represent individual mice. A and B, Boosting generated a vigorous secondary ASC 
response. ASC frequencies in draining popliteal (A) and iliac (B) lymph nodes were measured 5 
d after boosting (2º). The response in naïve mice (1º) is shown for comparison. Data are mean + 
SE (n = 3). C, Boosting significantly expanded the virus-specific ASC population in the BM. 
ASC frequencies are shown 8 wk after priming (1º) and 6 wk after boosting (2º). IgG ASCs 1º vs. 
2º, p < 0.005. Data are mean + SE (n = 4 for 1º and 9 for 2º). D, Boosting significantly increased 
circulating virus-specific IgG levels. Serum IgG levels determined by ELISA are shown 8 wk 
after priming (1º) and 6 wk after boosting (2º). IgG 1º vs. 2º, p < 0.0001. Data are mean + SE (n 
= 10-12). E, Boosting had no significant effect on virus-specific ASC numbers in the lung. ASC 
frequencies are shown 8 wk after priming (1º) and 6 wk after boosting (2º). Data are mean + SE 
(n = 3 for 1º and 8 for 2º). F, Boosting had no significant effect on virus-specific IgG BMem 
numbers in the lung. BMem frequencies are shown 8 wk after priming (1º) and 6 wk after boosting 
(2º). Data are mean + SE (n = 3-4). 
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Figure 7. Contrasting patterns of influenza-specific B memory localization in the lung after i.n. 
infection and i.m. vaccination. Data are presented from (Joo, He et al. 2008) showing virus-
specific ASC and BMem frequencies 8-12 wk after i.n. influenza infection (A and B). These data 
are compared with data selected from Fig. 6 of the current study showing virus-specific ASC and 
BMem frequencies after i.m. priming and boosting with inactivated influenza virus (C and D). 
Mice vaccinated i.m. were boosted at 8 wk and sampled 6 wk later. A and C, IgG and IgA ASCs 
are compared in the lung and BM (n = 5-12). B and D, IgG BMem frequencies are compared in the 
lung and spleen (n = 3-12). Data are mean + SE. 
 
105 
 
 
 
 
 
 
 
 
LIST OF REFERENCES  
 
 
 
 
 
106 
 
Abney, E. R., M. D. Cooper, et al. (1978). "Sequential expression of immunoglobulin on 
developing mouse B lymphocytes: a systematic survey that suggests a model for the 
generation of immunoglobulin isotype diversity." J Immunol 120(6): 2041-9. 
Ada, G. L. and P. D. Jones (1986). "The immune response to influenza infection." Curr Top 
Microbiol Immunol 128: 1-54. 
Adachi, M., S. Matsukura, et al. (1997). "Expression of cytokines on human bronchial epithelial 
cells induced by influenza virus A." Int Arch Allergy Immunol 113(1-3): 307-11. 
Ahmed, R. and D. Gray (1996). "Immunological memory and protective immunity: 
understanding their relation." Science 272(5258): 54-60. 
Allan, W., Z. Tabi, et al. (1990). "Cellular events in the lymph node and lung of mice with 
influenza. Consequences of depleting CD4+ T cells." J Immunol 144(10): 3980-6. 
Anderson, S. M., M. M. Tomayko, et al. (2006). "Intrinsic properties of human and murine 
memory B cells." Immunol Rev 211: 280-94. 
Asanuma, H., A. H. Thompson, et al. (1997). "Isolation and characterization of mouse nasal-
associated lymphoid tissue." J Immunol Methods 202(2): 123-31. 
Bachmann, M. F., T. M. Kundig, et al. (1994). "Free recirculation of memory B cells versus 
antigen-dependent differentiation to antibody-forming cells." J Immunol 153(8): 3386-97. 
Bachmayer, H. (1975). "Selective solubilization of hemagglutinin and neuraminidase from 
influenza viruses." Intervirology 5(5): 260-72. 
Baggiolini, M. (1998). "Chemokines and leukocyte traffic." Nature 392(6676): 565-8. 
107 
 
Baumgarth, N., O. C. Herman, et al. (2000). "B-1 and B-2 cell-derived immunoglobulin M 
antibodies are nonredundant components of the protective response to influenza virus 
infection." J Exp Med 192(2): 271-80. 
Bell, J. and D. Gray (2003). "Antigen-capturing cells can masquerade as memory B cells." J Exp 
Med 197(10): 1233-44. 
Bender, B. S., T. Croghan, et al. (1992). "Transgenic mice lacking class I major 
histocompatibility complex-restricted T cells have delayed viral clearance and increased 
mortality after influenza virus challenge." J Exp Med 175(4): 1143-5. 
Bender, B. S. and P. A. Small, Jr. (1992). "Influenza: pathogenesis and host defense." Semin 
Respir Infect 7(1): 38-45. 
Bernasconi, N. L., E. Traggiai, et al. (2002). "Maintenance of serological memory by polyclonal 
activation of human memory B cells." Science 298(5601): 2199-202. 
Blink, E. J., A. Light, et al. (2005). "Early appearance of germinal center-derived memory B 
cells and plasma cells in blood after primary immunization." J Exp Med 201(4): 545-54. 
Brady, M. I. and I. G. Furminger (1976). "A surface antigen influenza vaccine. 1. Purification of 
haemagglutinin and neuraminidase proteins." J Hyg (Lond) 77(2): 161-72. 
Brady, M. I. and I. G. Furminger (1976). "A surface antigen influenza vaccine. 2. Pyrogenicity 
and antigenicity." J Hyg (Lond) 77(2): 173-80. 
Brown, D. M., E. Roman, et al. (2004). "CD4 T cell responses to influenza infection." Semin 
Immunol 16(3): 171-7. 
108 
 
Brucher, J., I. Domke, et al. (1984). "Experimental infection of inbred mice with herpes simplex 
virus. VI. Effect of interferon on in vitro virus replication in macrophages." Arch Virol 
82(1-2): 83-93. 
Bussfeld, D., A. Kaufmann, et al. (1998). "Differential mononuclear leukocyte attracting 
chemokine production after stimulation with active and inactivated influenza A virus." 
Cell Immunol 186(1): 1-7. 
Carragher, D. M., J. Rangel-Moreno, et al. (2008). "Ectopic lymphoid tissues and local 
immunity." Semin Immunol 20(1): 26-42. 
Cassese, G., S. Lindenau, et al. (2001). "Inflamed kidneys of NZB / W mice are a major site for 
the homeostasis of plasma cells." Eur J Immunol 31(9): 2726-32. 
Cauley, L. S., T. Cookenham, et al. (2002). "Cutting edge: virus-specific CD4+ memory T cells 
in nonlymphoid tissues express a highly activated phenotype." J Immunol 169(12): 6655-
8. 
Coffman, R. L. and M. Cohn (1977). "The class of surface immunoglobulin on virgin and 
memory B lymphocytes." J Immunol 118(5): 1806-15. 
Cox, R. J., K. A. Brokstad, et al. (2004). "Influenza virus: immunity and vaccination strategies. 
Comparison of the immune response to inactivated and live, attenuated influenza 
vaccines." Scand J Immunol 59(1): 1-15. 
Crotty, S., R. D. Aubert, et al. (2004). "Tracking human antigen-specific memory B cells: a 
sensitive and generalized ELISPOT system." J Immunol Methods 286(1-2): 111-22. 
109 
 
Csencsits, K. L., M. A. Jutila, et al. (1999). "Nasal-associated lymphoid tissue: phenotypic and 
functional evidence for the primary role of peripheral node addressin in naive lymphocyte 
adhesion to high endothelial venules in a mucosal site." J Immunol 163(3): 1382-9. 
Cyster, J. G. (2003). "Homing of antibody secreting cells." Immunol Rev 194: 48-60. 
Cyster, J. G. (2005). "Chemokines, sphingosine-1-phosphate, and cell migration in secondary 
lymphoid organs." Annu Rev Immunol 23: 127-59. 
Davenport, F. M., A. V. Hennessy, et al. (1964). "Comparisons of Serologic and Febrile 
Responses in Humans to Vaccination with Influenza a Viruses or Their Hemagglutinins." 
J Lab Clin Med 63: 5-13. 
Dawson, T. C., M. A. Beck, et al. (2000). "Contrasting effects of CCR5 and CCR2 deficiency in 
the pulmonary inflammatory response to influenza A virus." Am J Pathol 156(6): 1951-9. 
Di Rosa, F. and R. Pabst (2005). "The bone marrow: a nest for migratory memory T cells." 
Trends Immunol 26(7): 360-6. 
Doherty, P. C. and J. P. Christensen (2000). "Accessing complexity: the dynamics of virus-
specific T cell responses." Annu Rev Immunol 18: 561-92. 
Doherty, P. C., D. J. Topham, et al. (1997). "Effector CD4+ and CD8+ T-cell mechanisms in the 
control of respiratory virus infections." Immunol Rev 159: 105-17. 
Dorner, T. and A. Radbruch (2005). "Selecting B cells and plasma cells to memory." J Exp Med 
201(4): 497-9. 
Doucett, V. P., W. Gerhard, et al. (2005). "Enumeration and characterization of virus-specific B 
cells by multicolor flow cytometry." J Immunol Methods 303(1-2): 40-52. 
110 
 
Eichelberger, M. C., M. L. Wang, et al. (1991). "Influenza virus RNA in the lung and lymphoid 
tissue of immunologically intact and CD4-depleted mice." J Gen Virol 72 ( Pt 7): 1695-8. 
Feng, C. G., W. J. Britton, et al. (2000). "Up-regulation of VCAM-1 and differential expansion 
of beta integrin-expressing T lymphocytes are associated with immunity to pulmonary 
Mycobacterium tuberculosis infection." J Immunol 164(9): 4853-60. 
Flynn, K. J., G. T. Belz, et al. (1998). "Virus-specific CD8+ T cells in primary and secondary 
influenza pneumonia." Immunity 8(6): 683-91. 
Fujisawa, H., S. Tsuru, et al. (1987). "Protective mechanisms against pulmonary infection with 
influenza virus. I. Relative contribution of polymorphonuclear leukocytes and of alveolar 
macrophages to protection during the early phase of intranasal infection." J Gen Virol 68 
( Pt 2): 425-32. 
Garcia-Sastre, A., R. K. Durbin, et al. (1998). "The role of interferon in influenza virus tissue 
tropism." J Virol 72(11): 8550-8. 
Gerdil, C. (2003). "The annual production cycle for influenza vaccine." Vaccine 21(16): 1776-9. 
Gerhard, W., K. Mozdzanowska, et al. (1997). "Role of the B-cell response in recovery of mice 
from primary influenza virus infection." Immunol Rev 159: 95-103. 
Glezen, W. P. (1982). "Serious morbidity and mortality associated with influenza epidemics." 
Epidemiol Rev 4: 25-44. 
Gorse, G. J., M. J. Campbell, et al. (1995). "Increased anti-influenza A virus cytotoxic T cell 
activity following vaccination of the chronically ill elderly with live attenuated or 
inactivated influenza virus vaccine." J Infect Dis 172(1): 1-10. 
111 
 
Graham, M. B. and T. J. Braciale (1997). "Resistance to and recovery from lethal influenza virus 
infection in B lymphocyte-deficient mice." J Exp Med 186(12): 2063-8. 
Haller, O., H. Arnheiter, et al. (1979). "Genetically determined, interferon-dependent resistance 
to influenza virus in mice." J Exp Med 149(3): 601-12. 
Halper, J., S. M. Fu, et al. (1978). "Patterns of expression of human "Ia-like" antigens during the 
terminal stages of B cell development." J Immunol 120(5): 1480-4. 
Hamilton-Easton, A. and M. Eichelberger (1995). "Virus-specific antigen presentation by 
different subsets of cells from lung and mediastinal lymph node tissues of influenza 
virus-infected mice." J Virol 69(10): 6359-66. 
Harper, S. A., K. Fukuda, et al. (2005). "Prevention and control of influenza. Recommendations 
of the Advisory Committee on Immunization Practices (ACIP)." MMWR Recomm Rep 
54(RR-8): 1-40. 
Hauser, A. E., G. F. Debes, et al. (2002). "Chemotactic responsiveness toward ligands for 
CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory 
immune response." J Immunol 169(3): 1277-82. 
Hebeis, B. J., K. Klenovsek, et al. (2004). "Activation of virus-specific memory B cells in the 
absence of T cell help." J Exp Med 199(4): 593-602. 
Hicks, J. T., F. A. Ennis, et al. (1978). "The importance of an intact complement pathway in 
recovery from a primary viral infection: influenza in decomplemented and in C5-
deficient mice." J Immunol 121(4): 1437-45. 
Hilleman, M. R. (2000). "Vaccines in historic evolution and perspective: a narrative of vaccine 
discoveries." Vaccine 18(15): 1436-47. 
112 
 
Hofmann, P., H. Sprenger, et al. (1997). "Susceptibility of mononuclear phagocytes to influenza 
A virus infection and possible role in the antiviral response." J Leukoc Biol 61(4): 408-14. 
Hogan, R. J., E. J. Usherwood, et al. (2001). "Activated antigen-specific CD8+ T cells persist in 
the lungs following recovery from respiratory virus infections." J Immunol 166(3): 1813-
22. 
Hogan, R. J., W. Zhong, et al. (2001). "Protection from respiratory virus infections can be 
mediated by antigen-specific CD4(+) T cells that persist in the lungs." J Exp Med 193(8): 
981-6. 
Huckriede, A., L. Bungener, et al. (2003). "Influenza virosomes: combining optimal presentation 
of hemagglutinin with immunopotentiating activity." Vaccine 21(9-10): 925-31. 
Hyland, L., M. Sangster, et al. (1994). "Respiratory virus infection of mice provokes a permanent 
humoral immune response." J Virol 68(9): 6083-6. 
Ingold, K., A. Zumsteg, et al. (2005). "Identification of proteoglycans as the APRIL-specific 
binding partners." J Exp Med 201(9): 1375-83. 
Jones, C. A., M. Fernandez, et al. (2003). "Herpes simplex virus type 2 induces rapid cell death 
and functional impairment of murine dendritic cells in vitro." J Virol 77(20): 11139-49. 
Jones, P. D. and G. L. Ada (1986). "Influenza virus-specific antibody-secreting cells in the 
murine lung during primary influenza virus infection." J Virol 60(2): 614-9. 
Jones, P. D. and G. L. Ada (1987). "Persistence of influenza virus-specific antibody-secreting 
cells and B-cell memory after primary murine influenza virus infection." Cell Immunol 
109(1): 53-64. 
113 
 
Joo, H. M., Y. He, et al. (2008). "Broad dispersion and lung localization of virus-specific 
memory B cells induced by influenza pneumonia." Proc Natl Acad Sci U S A 105(9): 
3485-90. 
Kim, C. H. (2004). "Chemokine-chemokine receptor network in immune cell trafficking." Curr 
Drug Targets Immune Endocr Metabol Disord 4(4): 343-61. 
Kopf, M., B. Abel, et al. (2002). "Complement component C3 promotes T-cell priming and lung 
migration to control acute influenza virus infection." Nat Med 8(4): 373-8. 
Kopf, M., F. Brombacher, et al. (2002). "Role of IgM antibodies versus B cells in influenza 
virus-specific immunity." Eur J Immunol 32(8): 2229-36. 
Kunzel, W., H. Glathe, et al. (1996). "Kinetics of humoral antibody response to trivalent 
inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the 
first time." Vaccine 14(12): 1108-10. 
La Gruta, N. L., K. Kedzierska, et al. (2007). "A question of self-preservation: immunopathology 
in influenza virus infection." Immunol Cell Biol 85(2): 85-92. 
Langlois, R. A. and K. L. Legge (2007). "Respiratory dendritic cells: mediators of tolerance and 
immunity." Immunol Res 39(1-3): 128-45. 
Lawrence, C. W., R. M. Ream, et al. (2005). "Frequency, specificity, and sites of expansion of 
CD8+ T cells during primary pulmonary influenza virus infection." J Immunol 174(9): 
5332-40. 
Legge, K. L. and T. J. Braciale (2003). "Accelerated migration of respiratory dendritic cells to 
the regional lymph nodes is limited to the early phase of pulmonary infection." Immunity 
18(2): 265-77. 
114 
 
Li, X., D. J. Vanitha, et al. (2006). "A strategy for selective, CD4+ T cell-independent activation 
of virus-specific memory B cells for limiting dilution analysis." J Immunol Methods 
313(1-2): 110-8. 
Liang, B., L. Hyland, et al. (2001). "Nasal-associated lymphoid tissue is a site of long-term 
virus-specific antibody production following respiratory virus infection of mice." J Virol 
75(11): 5416-20. 
Lindenmann, J., C. A. Lane, et al. (1963). "The Resistance of A2g Mice to Myxoviruses." J 
Immunol 90: 942-51. 
Liu, Y. J., C. Barthelemy, et al. (1995). "Memory B cells from human tonsils colonize mucosal 
epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-
2." Immunity 2(3): 239-48. 
Luster, A. D., R. Alon, et al. (2005). "Immune cell migration in inflammation: present and future 
therapeutic targets." Nat Immunol 6(12): 1182-90. 
Manz, R. A., M. Lohning, et al. (1998). "Survival of long-lived plasma cells is independent of 
antigen." Int Immunol 10(11): 1703-11. 
Manz, R. A., A. Thiel, et al. (1997). "Lifetime of plasma cells in the bone marrow." Nature 
388(6638): 133-4. 
Marshall, D., R. Sealy, et al. (1999). "TH cells primed during influenza virus infection provide 
help for qualitatively distinct antibody responses to subsequent immunization." J 
Immunol 163(9): 4673-82. 
Marshall, D. R., S. J. Turner, et al. (2001). "Measuring the diaspora for virus-specific CD8+ T 
cells." Proc Natl Acad Sci U S A 98(11): 6313-8. 
115 
 
Masopust, D., V. Vezys, et al. (2001). "Preferential localization of effector memory cells in 
nonlymphoid tissue." Science 291(5512): 2413-7. 
Matsukura, S., F. Kokubu, et al. (1996). "Expression of IL-6, IL-8, and RANTES on human 
bronchial epithelial cells, NCI-H292, induced by influenza virus A." J Allergy Clin 
Immunol 98(6 Pt 1): 1080-7. 
Mazo, I. B., M. Honczarenko, et al. (2005). "Bone marrow is a major reservoir and site of 
recruitment for central memory CD8+ T cells." Immunity 22(2): 259-70. 
McDermott, M. R. and J. Bienenstock (1979). "Evidence for a common mucosal immunologic 
system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues." J 
Immunol 122(5): 1892-8. 
McHeyzer-Williams, L. J., D. J. Driver, et al. (2001). "Germinal center reaction." Curr Opin 
Hematol 8(1): 52-9. 
McHeyzer-Williams, L. J. and M. G. McHeyzer-Williams (2005). "Antigen-specific memory B 
cell development." Annu Rev Immunol 23: 487-513. 
Mora, J. R., M. Iwata, et al. (2006). "Generation of gut-homing IgA-secreting B cells by 
intestinal dendritic cells." Science 314(5802): 1157-60. 
Mora, J. R. and U. H. von Andrian (2009). "Role of retinoic acid in the imprinting of gut-homing 
IgA-secreting cells." Semin Immunol 21(1): 28-35. 
Moser, C. A. and P. A. Offit (2001). "Distribution of rotavirus-specific memory B cells in gut-
associated lymphoid tissue after primary immunization." J Gen Virol 82(Pt 9): 2271-4. 
116 
 
Moyron-Quiroz, J. E., J. Rangel-Moreno, et al. (2006). "Persistence and responsiveness of 
immunologic memory in the absence of secondary lymphoid organs." Immunity 25(4): 
643-54. 
Moyron-Quiroz, J. E., J. Rangel-Moreno, et al. (2004). "Role of inducible bronchus associated 
lymphoid tissue (iBALT) in respiratory immunity." Nat Med 10(9): 927-34. 
Muehlinghaus, G., L. Cigliano, et al. (2005). "Regulation of CXCR3 and CXCR4 expression 
during terminal differentiation of memory B cells into plasma cells." Blood 105(10): 
3965-71. 
Murphy, B. R. and M. L. Clements (1989). "The systemic and mucosal immune response of 
humans to influenza A virus." Curr Top Microbiol Immunol 146: 107-16. 
Murphy, B. R. and K. Coelingh (2002). "Principles underlying the development and use of live 
attenuated cold-adapted influenza A and B virus vaccines." Viral Immunol 15(2): 295-
323. 
Nanan, R., D. Heinrich, et al. (2001). "Acute and long-term effects of booster immunisation on 
frequencies of antigen-specific memory B-lymphocytes." Vaccine 20(3-4): 498-504. 
Nanki, T., K. Hayashida, et al. (2000). "Stromal cell-derived factor-1-CXC chemokine receptor 4 
interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis 
synovium." J Immunol 165(11): 6590-8. 
Neutra, M. R. and P. A. Kozlowski (2006). "Mucosal vaccines: the promise and the challenge." 
Nat Rev Immunol 6(2): 148-58. 
Nichol, K. L. and J. J. Treanor (2006). "Vaccines for seasonal and pandemic influenza." J Infect 
Dis 194 Suppl 2: S111-8. 
117 
 
Nicholson, K. G. (1992). "Clinical features of influenza." Semin Respir Infect 7(1): 26-37. 
O'Connor, B. P., V. S. Raman, et al. (2004). "BCMA is essential for the survival of long-lived 
bone marrow plasma cells." J Exp Med 199(1): 91-8. 
Ochsenbein, A. F., D. D. Pinschewer, et al. (2000). "Protective long-term antibody memory by 
antigen-driven and T help-dependent differentiation of long-lived memory B cells to 
short-lived plasma cells independent of secondary lymphoid organs." Proc Natl Acad Sci 
U S A 97(24): 13263-8. 
Okumura, K., M. H. Julius, et al. (1976). "Demonstration that IgG memory is carried by IgG-
bearing cells." Eur J Immunol 6(7): 467-72. 
Ostler, T., T. Hussell, et al. (2001). "Long-term persistence and reactivation of T cell memory in 
the lung of mice infected with respiratory syncytial virus." Eur J Immunol 31(9): 2574-82. 
Perrin, P. and S. Morgeaux (1995). "Inactivation of DNA by beta-propiolactone." Biologicals 
23(3): 207-11. 
Persson, C. G., J. S. Erjefalt, et al. (1998). "Contribution of plasma-derived molecules to mucosal 
immune defence, disease and repair in the airways." Scand J Immunol 47(4): 302-13. 
Powers, D. C., G. E. Smith, et al. (1995). "Influenza A virus vaccines containing purified 
recombinant H3 hemagglutinin are well tolerated and induce protective immune 
responses in healthy adults." J Infect Dis 171(6): 1595-9. 
Reid, A. H., T. G. Fanning, et al. (2004). "Novel origin of the 1918 pandemic influenza virus 
nucleoprotein gene." J Virol 78(22): 12462-70. 
Reid, A. H., J. K. Taubenberger, et al. (2004). "Evidence of an absence: the genetic origins of the 
1918 pandemic influenza virus." Nat Rev Microbiol 2(11): 909-14. 
118 
 
Reinhardt, R. L., A. Khoruts, et al. (2001). "Visualizing the generation of memory CD4 T cells 
in the whole body." Nature 410(6824): 101-5. 
Riberdy, J. M., J. P. Christensen, et al. (2000). "Diminished primary and secondary influenza 
virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice." J Virol 74(20): 
9762-5. 
Ridderstad, A. and D. M. Tarlinton (1998). "Kinetics of establishing the memory B cell 
population as revealed by CD38 expression." J Immunol 160(10): 4688-95. 
Rodrigo Mora, J. and U. H. Von Andrian (2006). "Specificity and plasticity of memory 
lymphocyte migration." Curr Top Microbiol Immunol 308: 83-116. 
Roman, E., E. Miller, et al. (2002). "CD4 effector T cell subsets in the response to influenza: 
heterogeneity, migration, and function." J Exp Med 196(7): 957-68. 
Ronni, T., T. Sareneva, et al. (1995). "Activation of IFN-alpha, IFN-gamma, MxA, and IFN 
regulatory factor 1 genes in influenza A virus-infected human peripheral blood 
mononuclear cells." J Immunol 154(6): 2764-74. 
Rott, R., H. D. Klenk, et al. (1995). "Influenza viruses, cell enzymes, and pathogenicity." Am J 
Respir Crit Care Med 152(4 Pt 2): S16-9. 
Roy, M. P., C. H. Kim, et al. (2002). "Cytokine control of memory B cell homing machinery." J 
Immunol 169(4): 1676-82. 
Sangster, M., L. Hyland, et al. (1995). "Distinctive kinetics of the antibody-forming cell response 
to Sendai virus infection of mice in different anatomical compartments." Virology 207(1): 
287-91. 
119 
 
Sangster, M., F. S. Smith, et al. (1995). "Human parainfluenza virus type 1 immunization of 
infant mice protects from subsequent Sendai virus infection." Virology 212(1): 13-9. 
Sangster, M. Y., X. Y. Mo, et al. (1997). "Matching antibody class with pathogen type and portal 
of entry: cognate mechanisms regulate local isotype expression patterns in lymph nodes 
draining the respiratory tract of mice inoculated with respiratory viruses, according to 
virus replication competence and site of inoculation." J Immunol 159(4): 1893-902. 
Sangster, M. Y., J. M. Riberdy, et al. (2003). "An early CD4+ T cell-dependent immunoglobulin 
A response to influenza infection in the absence of key cognate T-B interactions." J Exp 
Med 198(7): 1011-21. 
Sangster, M. Y., D. J. Topham, et al. (2000). "Analysis of the virus-specific and nonspecific B 
cell response to a persistent B-lymphotropic gammaherpesvirus." J Immunol 164(4): 
1820-8. 
Sarawar, S. R. and P. C. Doherty (1994). "Concurrent production of interleukin-2, interleukin-10, 
and gamma interferon in the regional lymph nodes of mice with influenza pneumonia." J 
Virol 68(5): 3112-9. 
Schittek, B. and K. Rajewsky (1990). "Maintenance of B-cell memory by long-lived cells 
generated from proliferating precursors." Nature 346(6286): 749-51. 
Shaw, M. W., N. H. Arden, et al. (1992). "New aspects of influenza viruses." Clin Microbiol Rev 
5(1): 74-92. 
Shimoda, M., T. Nakamura, et al. (2001). "Isotype-specific selection of high affinity memory B 
cells in nasal-associated lymphoid tissue." J Exp Med 194(11): 1597-607. 
120 
 
Slifka, M. K. and R. Ahmed (1996). "Limiting dilution analysis of virus-specific memory B cells 
by an ELISPOT assay." J Immunol Methods 199(1): 37-46. 
Slifka, M. K. and R. Ahmed (1996). "Long-term humoral immunity against viruses: revisiting 
the issue of plasma cell longevity." Trends Microbiol 4(10): 394-400. 
Slifka, M. K., R. Antia, et al. (1998). "Humoral immunity due to long-lived plasma cells." 
Immunity 8(3): 363-72. 
Slifka, M. K., M. Matloubian, et al. (1995). "Bone marrow is a major site of long-term antibody 
production after acute viral infection." J Virol 69(3): 1895-902. 
Smith, K. G., A. Light, et al. (1997). "The extent of affinity maturation differs between the 
memory and antibody-forming cell compartments in the primary immune response." 
EMBO J 16(11): 2996-3006. 
Spiekermann, G. M., P. W. Finn, et al. (2002). "Receptor-mediated immunoglobulin G transport 
across mucosal barriers in adult life: functional expression of FcRn in the mammalian 
lung." J Exp Med 196(3): 303-10. 
Sprenger, H., R. G. Meyer, et al. (1996). "Selective induction of monocyte and not neutrophil-
attracting chemokines after influenza A virus infection." J Exp Med 184(3): 1191-6. 
Steinhauer, D. A. (1999). "Role of hemagglutinin cleavage for the pathogenicity of influenza 
virus." Virology 258(1): 1-20. 
Subbarao, K. and T. Joseph (2007). "Scientific barriers to developing vaccines against avian 
influenza viruses." Nat Rev Immunol 7(4): 267-78. 
Tangye, S. G., D. T. Avery, et al. (2003). "A division-linked mechanism for the rapid generation 
of Ig-secreting cells from human memory B cells." J Immunol 170(1): 261-9. 
121 
 
Thomas, P. G., R. Keating, et al. (2006). "Cell-mediated protection in influenza infection." 
Emerg Infect Dis 12(1): 48-54. 
Thompson, W. W., D. K. Shay, et al. (2003). "Mortality associated with influenza and 
respiratory syncytial virus in the United States." JAMA 289(2): 179-86. 
Topham, D. J. and P. C. Doherty (1998). "Clearance of an influenza A virus by CD4+ T cells is 
inefficient in the absence of B cells." J Virol 72(1): 882-5. 
Topham, D. J. and P. C. Doherty (1998). "Longitudinal analysis of the acute Sendai virus-
specific CD4+ T cell response and memory." J Immunol 161(9): 4530-5. 
Topham, D. J., R. A. Tripp, et al. (1997). "CD8+ T cells clear influenza virus by perforin or Fas-
dependent processes." J Immunol 159(11): 5197-200. 
Topham, D. J., R. A. Tripp, et al. (1996). "Quantitative analysis of the influenza virus-specific 
CD4+ T cell memory in the absence of B cells and Ig." J Immunol 157(7): 2947-52. 
Tripp, R. A., S. R. Sarawar, et al. (1995). "Characteristics of the influenza virus-specific CD8+ T 
cell response in mice homozygous for disruption of the H-2lAb gene." J Immunol 155(6): 
2955-9. 
Ueda, Y., K. Yang, et al. (2004). "Inflammation controls B lymphopoiesis by regulating 
chemokine CXCL12 expression." J Exp Med 199(1): 47-58. 
Underhill, G. H., H. A. Minges Wols, et al. (2002). "IgG plasma cells display a unique spectrum 
of leukocyte adhesion and homing molecules." Blood 99(8): 2905-12. 
van Panhuys, N., R. Perret, et al. (2005). "Effector lymphoid tissue and its crucial role in 
protective immunity." Trends Immunol 26(5): 242-7. 
122 
 
Vanitha, D. J., H. M. Joo, et al. (2007). "Quantitative analysis of herpes simplex virus type 1-
specific memory B cells generated by different routes of infection." Virology 360(1): 
136-42. 
Vieira, P. and K. Rajewsky (1990). "Persistence of memory B cells in mice deprived of T cell 
help." Int Immunol 2(6): 487-94. 
Walker, J. A., T. Sakaguchi, et al. (1992). "Location and character of the cellular enzyme that 
cleaves the hemagglutinin of a virulent avian influenza virus." Virology 190(1): 278-87. 
Webby, R. J., S. Andreansky, et al. (2003). "Protection and compensation in the influenza virus-
specific CD8+ T cell response." Proc Natl Acad Sci U S A 100(12): 7235-40. 
Wilson, I. A. and N. J. Cox (1990). "Structural basis of immune recognition of influenza virus 
hemagglutinin." Annu Rev Immunol 8: 737-71. 
Wong, P. and E. G. Pamer (2003). "CD8 T cell responses to infectious pathogens." Annu Rev 
Immunol 21: 29-70. 
Woodland, D. L. (2003). "Cell-mediated immunity to respiratory virus infections." Curr Opin 
Immunol 15(4): 430-5. 
Wrammert, J., K. Smith, et al. (2008). "Rapid cloning of high-affinity human monoclonal 
antibodies against influenza virus." Nature 453(7195): 667-71. 
Xu, B., N. Wagner, et al. (2003). "Lymphocyte homing to bronchus-associated lymphoid tissue 
(BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 
adhesion pathways." J Exp Med 197(10): 1255-67. 
Yefenof, E., V. M. Sanders, et al. (1986). "In vitro activation of murine antigen-specific memory 
B cells by a T-dependent antigen." J Immunol 137(1): 85-90. 
123 
 
Zammit, D. J., D. L. Turner, et al. (2006). "Residual antigen presentation after influenza virus 
infection affects CD8 T cell activation and migration." Immunity 24(4): 439-49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
 Vita 
Hye Mee Joo was born May 4, 1980 in Seoul, South Korea. She graduated from attached girls’ 
high school to the college of education, Hongik University in 1999. She attended Hallym 
University in Chunchon where she received her B.A. in Genetic engineering in 2003. She began 
here graduate studies at the University of Tennessee, Knoxville in Spring 2005. She graduated 
with a Doctor of Philosophy in Comparative and Experimental Medicine in the summer of 2009. 
 
 
